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3Abstract
Cholangiocarcinoma (CCA) is a rare cancer with a poor prognosis. Much of medical
research has focused on investigating cancers with a higher incidence and little focus
has been devoted to this disease.
The aim of this thesis was to perform a protein analysis of CCA and cholangiocyte cell
lines. Differences between immortalised cancer and normal cells were sought in
order to identify potential therapeutic targets and/or diagnostic tools.
A variety of CCA cell lines were used, reflecting both intra and extrahepatic disease.
The different subtypes of CCA through the developed and developing world are also
represented so differences were also sought between them. Proteomic analysis was
performed using DIGE with subsequent spot selection. Identified spots were
extracted and processed using mass spectrometry.
In addition, available chemotherapy agents were tested in vitro against the same cell
lines to check for their action and how this could be enhanced. A benzodiazepine
receptor antagonist (PK11195) was used to demonstrate apoptosis promotion in the
presence of established cytotoxic agents (gemcitabine, etoposide, 5 fluorouracil and
cisplatin). Cytotoxic assays were carried out using the SRB (Sulphorhodamine B)
assay. Cell lines were tested for benzodiazepine receptor status using qRTPCR and
response was correlated.
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1 General Introduction
1.1 Cholangiocarcinoma
Cholangiocarcinoma (CCA) is a rare hepatobiliary tumour that arises from biliary
epithelium. The word’s etymology comes from Greek for bile (χολή, chole) duct
(αγγείον, angion) and cancer (καρκίνωμα, carcinoma). The disease was first
described in 1911 where it was distinguished from hepatomas (hepatocellular
carcinomas) on the basis of its cellular derivation (Goldzieher and von Bokay, 1911).
Although infrequent, it represents the second most common primary hepatobiliary
malignancy.
1.1.1 Incidence and epidemiology
In the western world the annual incidence of cholangiocarcinoma is typically 1 to 2
cases per 100,000 population (Renard et al., 1987, Landis et al., 1998). This translates
to roughly 1,000 cases per year in the United Kingdom and 9,000 cases per year in
the United States. However, the incidence varies considerably around the world and
can be much higher in developing countries, especially in the Far East, often
reflecting the disease’s different aetiologies. In Thailand for example, annual
incidence has been calculated to be in excess of 100 cases per 100,000 population
translating to about 60,000 cases per year (Green et al., 1991).
Data reveal that over the past few decades the incidence of CCA has been on the
increase both in the west and in the Far East (West et al., 2006, Khan et al., 2002b).
In the United States, intrahepatic CCA saw a rise in incidence of 165% between the
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periods 1975-1979 and 1995-1999 (Shaib et al., 2004). The cause of this rise is
unknown and does not appear to be explained simply by changes in coding practice
or by improvements in diagnosis (Khan et al., 2002a).
CCA accounts for less than 2% of all cancer diagnoses worldwide (Chamberlain and
Blumgart, 2000), however, it accounts for approximately 10 to 15% of all primary
hepatobiliary malignancies making it the second most common in this group
(Chapman, 1999, Ries LAG, 2005).
1.1.2 Classification and histology
Cholangiocarcinomas can develop anywhere along the biliary tree from the ampulla
of Vater to the intrahepatic biliary radicals. The term “cholangiocarcinoma” was
originally used to refer exclusively to primary tumours of the intrahepatic bile ducts.
It was not used in reference to extrahepatic bile duct tumours, however, the term is
nowadays regarded as inclusive of intrahepatic, perihilar, and distal extrahepatic
tumours of the bile ducts (Albores-Saavedra et al., 1991).
CCAs are usually categorised according to their anatomic location:
 intrahepatic bile ducts (intrahepatic CCA is also sometimes referred to as
‘peripheral’), which represent 20-25% of the total
 extrahepatic bile ducts (extrahepatic CCA), which also represent 20-25%
 hilar CCAs, representing 50-60% of all cases of cholangiocarcinoma. Tumours that
involve the bifurcation of the ducts are often referred to as Klatskin tumours and
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are sub categorised using the Bismuth classification (Bismuth and Castaing,
1994).
o Type I - tumours found below the confluence of the right and left hepatic
ducts;
o Type II - tumours reaching the confluence but not involving the right or left
hepatic ducts;
o Type III - tumours occluding the common hepatic duct and either the right
(IIIa) or left (IIIb) hepatic duct;
o Type IV - tumours that are multicentric or they involve the confluence and
both the right and left hepatic ducts.
Hilar CCAs have often been grouped with either intra or extrahepatic CCAs. Examples
include death certification, where Klatskin tumours have been recorded as
intrahepatic (Khan et al., 2002a) whilst in other instances they have been classified
as extrahepatic (Chamberlain and Blumgart, 2000).
A method for themacroscopic classification of CCAs has yet to be universally agreed
on, on an international base at least. Several, mostly regional, classifications have
been used in the past and present, which often creates difficulties and confusion
particularly when comparing data. A commonly used classification system is the one
proposed by The Liver Cancer Study Group of Japan which characterises them as
mass forming, periductal infiltrating or intraductal (Lim and Park, 2004). Of these
morphological types, intraductal cholangiocarcinomas are the least common, but
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have a more favourable prognosis than either the mass-forming or periductular
infiltrating types.
Histologically cholangiocarcinomas are most commonly found to be well-
differentiated adenocarcinomas (95%) (Patel, 2006). The other 5% can be squamous
cell carcinomas, mucoepidermal carcinomas, rhabdomyosarcomas,
leiomyosarcomas, cystadenocarcinoma, granular cell carcinoma, lymphomas or
carcinoid tumours (Chapman, 1999).
1.1.3 Staging
There are currently three staging systems for CCA: the AJCC/UICC (American Joint
Cancer Committee/Union for International Cancer Control) TNM staging system, the
LCSGJ (Liver Cancer Study Group of Japan) (Yamasaki, 2003) and the NCCJ (National
Cancer Center of Japan) (Okabayashi et al., 2001). Intra, perihilar and extra hepatic
CCAs are staged according to different criteria. The 7th and most recent edition of
the TNM classification of malignant tumours was published in 2009 and Table 1
illustrates the staging of intrahepatic CCA (Sobin et al., 2010). A subsequent
validation study demonstrated that it was accurate in correlating increasing stage
with poor patient survival (Ribero et al., 2011).
Table 2 illustrates the TNM staging for perihilar CCA and Table 3 that of extra hepatic
CCA.
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T1 Solitary tumour without vascular invasion
T2a Solitary tumour with vascular invasion
T2b Multiple tumours, with or without vascular invasion
T3 Tumour(s) perforating the visceral peritoneum or involving the local extra
hepatic structures by direct invasion
T4 Tumour with periductal invasion
N0 no regional lymph node metastases
N1 regional lymph node metastases
M0 No distant metastases
M1 Distant metastases present
Stage
I T1 N0 M0
II T2 N0 M0
III T3 N0 M0
IVa T4 N0 M0, Any T N1 Mo
IVb Any T, Any N, M1
Table 1 TNM classification and staging of intra hepatic CCA
General Introduction
17
Tx Primary tumour cannot be assessed
Tis Carcinoma in situ
T1 Tumour confined to the bile duct, with extension up to the muscle layer
or fibrous tissue
T2A Tumour invades beyond the wall of the bile duct to surrounding adipose
tissue
T2B Tumour invades adjacent hepatic parenchyma
T3 Tumour invades unilateral branches of the portal vein or hepatic artery
T4 Tumour invades main portal vein or its branches bilaterally; or the
common hepatic artery; or the second-order biliary radical bilaterally; or
unilateral second order biliary radicals with contralateral portal vein or
hepatic artery involvement
N0 No regional lymph node metastases
N1 Regional lymph node metastases present (including nodes along the
cystic duct, common bile duct, hepatic artery, and portal vein)
N2 Metastases to periaortic, pericaval, superior mesenteric artery, and/or
celiac artery lymph nodes
M0 No distant metastases
M1 Distant metastases present
Stage
0 Tis N0 M0
I T1 N0 M0
II T2A-B N0 M0
IIIa T3 N0 M0
IIIb T1-3 N1 M0
IVa T4 N0-1 M0
IVb Any T N2 M0
Any T Any N M1
Table 2 TNM classification and staging of perihilar CCA
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TX Primary tumour cannot be assessed
T0 No evidence of primary tumour
Tis Carcinoma in situ
T1 Tumour confined to the bile duct histologically
T2 Tumour invades beyond the wall of the bile duct
T3 Tumour invades the gallbladder, pancreas, duodenum, or other adjacent
organs without involvement of the celiac axis, or the superior mesenteric
artery
T4 Tumour involves the celiac axis, or the superior mesenteric artery
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastases
N1 Regional lymph node metastases present
M0 No distant metastases
M1 Distant metastases present
Stage
0 Tis N0 M0
IA T1 N0 M0
IB T2 N0 M0
IIA T3 N0 M0
IIB T1 N1 M0
T2 N1 M0
T3 N1 M0
III T4 Any N M0
IV Any T Any N M1
Table 3 TNM classification and staging of extra hepatic CCA
1.1.4 Clinical presentation
Patients with extrahepatic or hilar cholangiocarcinoma almost invariably present
with symptoms of obstructive jaundice (90-98%). Weight loss is present in 29% of
patients, whilst 20% have abdominal pain and 9% have fever (Chamberlain and
Blumgart, 2000).
Patients with intrahepatic lesions often present with malaise, abdominal pain or just
weight loss. Some are identified incidentally as mass lesions on imaging studies
performed during investigation of other symptoms or pathologies. On clinical
presentation alone, it is often difficult to distinguish intrahepatic cholangiocarcinoma
from hepatic metastases from other malignancies (Patel, 2006).
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1.1.5 Risk factors and aetiology
At presentation, most patients are at an advanced age with 65% of patients being
over 65 years old. The overall average age of presentation is 50 years. Males have a
higher incidence with a 3:1 ratio to females (Chapman, 1999).
The strongest association of cholangiocarcinoma development is with diseases that
cause chronic inflammation of the biliary tract. Not surprisingly, primary sclerosing
cholangitis (PSC) is the commonest known predisposing factor for
cholangiocarcinoma in the UK with a calculated lifetime risk of 5–15% for the PSC
patient. This association persists irrespective of the presence of ulcerative colitis, a
disease closely linked to PSC.
Other risk factors include:
 Chronic intraductal gall stones.
 Bile duct adenoma and biliary papillomatosis.
 Caroli’s disease (an inherited condition characterised by cystic dilatation of
intrahepatic bile ducts giving a lifetime risk for CCA of 7%).
 Choledochal cysts (about 5% will transform, risk increases with age).
 Cirrhosis of any aetiology (Welzel et al., 2007).
 Smoking (increased risk in association with PSC).
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 Thorotrast, a radiological contrast medium with a half life of approximately
400 years. It is no longer licensed for clinical use and was withdrawn from the
market in the 1950s. After exposure, the relative risk for all hepatobiliary
malignancies has been reported between 39.2 and 47 and lasts for several
decades as Thorotrast is retained in the reticuloendothelial system and
continues to produce ionising radiation (Zhu et al., 2004).
Some risk factors such as Hepatitis C (especially with intrahepatic
cholangiocarcinoma) and heavy alcohol consumption have been associated with
cholangiocarcinoma but their role could not be independently evaluated from
cirrhosis (Shaib et al., 2007).
In South East Asia, where the tumour has a higher incidence, the additional
associated risk factors are:
 Liver flukes (Opisthorchis viverrini and Clonorchis sinensis), especially in Thailand,
Laos and northern Malaysia (Sripa and Pairojkul, 2008). This association was first
recognised in the literature approximately 60 years ago (Viranuvatti et al., 1955).
It has been suggested that the association of O. viverrini and CCA is the strongest
between any parasite and a cancer (Sripa et al., 2012).
 Chronic typhoid carrier status (which causes a six fold increased risk of all
hepatobiliary malignancies) (Welton et al., 1979).
General Introduction
21
1.1.6 Molecular pathogenesis
The malignant transformation of cholangiocytes, a process often referred to as
‘cholangiocarcinogenesis’ is still not fully understood. Current evidence implicates
conditions leading to an environment of chronic inflammation of the liver. Other
factors such as injury to the bile duct epithelium and alteration to bile flow,
especially obstruction, are usually linked to this chronic inflammation (Wise et al.,
2008). DNA damage as a result of the above conditions promotes tissue
proliferation, in a local environment that becomes rich in growth factors and
cytokines. Cells are therefore in a position to develop autonomous proliferation
through activation of pro-proliferative intracellular signalling pathways and
enhanced production of mitogenic factors.
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Figure 1-1 Proposed mechanisms leading to transformation of normal biliary cells into
malignant cholangiocytes.
Cholangiocarcinoma cells express altered molecular mechanisms, which enhance cell
proliferation, decrease apoptosis, and increase the capacity of tissue invasion, stromal
proliferation, and angiogenesis (Fava and Lorenzini, 2012).
Cytokines released by cholangiocytes and that have been implicated in
cholangiocarcinogenesis include: interleukin 6 (IL-6), transforming growth factor-β
(TGF-β), IL-8, tumour necrosis factor-α (TNF-α) and platelet–derived growth factor
(PDGF). These can act in both an autocrine and paracrine fashion (Fava and
Lorenzini, 2012). They stimulate several intracellular pathways involved in growth
and survival of malignant cholangiocytes.
IL-6 for instance activates the pro-survival p38 mitogen activated protein kinase and
up-regulates Mcl-1, an anti-apoptotic protein in the Bcl-2 family of apoptotic
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proteins (Kobayashi et al., 2005). This tips the balance in the pro and anti-apoptotic
equilibrium thereby shifting affected cells towards cell survival.
Mcl-1 up regulation in cholangiocytes also increases cancer cell resistance to TRAIL
(tumour necrosis factor related apoptosis inducing ligand) promoting cell survival.
The cytokine TGF-β along with its signalling pathway are associated with several cell
functions such as growth, survival, apoptosis, differentiation and immunity. In the
presence of cholestasis, cholangiocytes express TGF-β, however CCA cell mutations
to the receptors of TGF-β induce a resistance to the cytokine’s effect. The
impediment in TGF-β signalling also accounts for the enhanced deposition of fibrotic
(stromal) tissue, a characteristic feature of CCA (Yazumi et al., 2000).
Nitric oxide is an agent with recognised mutagenic properties. Cytokines released in
response to inflammation activate iNOS (inducible nitric oxide synthase) which in
turn generates nitric oxide. Nitric oxide in turn can directly or through the formation
of peroxynitrite species lead to the deamination of guanine and DNA adduct
formation thereby promoting DNA mutations (Jaiswal et al., 2000, Jaiswal et al.,
2001). iNOS has also been shown to promote the up-regulation of COX-2 in in-vitro
studies of immortalized mouse cholangiocytes suggesting that COX-2 and COX-2
derived prostanoids could have a key role in cholangiocarcinogenesis. COX-2 also up
regulated the expression of Notch-1, a trans membrane receptor involved in cell
proliferation, which has been implicated in other cancers (Ishimura et al., 2005).
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1.1.7 Current treatment of cholangiocarcinoma
1.1.7.1 Surgery
1.1.7.1.1 Resection
Patients are usually assessed for surgery before being considered for other
treatments. Surgical resection for CCA gained favour in the early 1970s (Okaro et al.,
2002). It remains a major undertaking with relatively high morbidity and mortality
rates, however, it is the only treatment modality that can offer potential for cure.
Morbidity figures range for 31 to 85% and perioperative mortality from 5 to 10%
(Meza-Junco et al., 2010).
Less than 25% of patients with CCA are amenable to surgical resection at the time of
presentation. When R0 resection is achieved, reported five-year survival rates range
from 30% to 41% for hilar CCA, 31% to 63% for intrahepatic tumours and 27% to 37%
for extrahepatic tumours. This rate has not appreciably improved over recent years
(Meza-Junco et al., 2010, Wade et al., 1997).
1.1.7.1.2 Liver transplantation
More recently, liver transplantation has been championed as an alternative surgical
option for peripheral CCA with potential curative outcomes. Early attempts of its use
were fraught with high recurrence rates (Robles et al., 2004). However, the latest
outcomes presented by the Mayo Clinic Rochester, where an aggressive neo-
adjuvant regime is employed, claim a 5 year survival rate (in 90 transplanted
patients) in excess of 70% (Rosen et al., 2008). These figures compare favourably to
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surgical resection. Very importantly however, is that they also compare well to
survival figures in patients that receive liver transplants for other diagnoses. This
justifies the argument of using donor livers for this purpose at least on a clinical trial
stage. To date however, the evidence as illustrated above comes from non-
randomised case series and has not been widely replicated in other parts of the
world.
1.1.7.2 Palliative treatment
The remaining 75% of patients, who are not candidates for surgical resection, can be
considered for palliative treatment. There are various supportive treatment regimes
and the algorithm of treatment can be complex (see Figure 1-2). Factors that can
affect treatment decisions include:
 Anatomical location of primary and/or metastatic disease
 Symptoms (eg jaundice)
 Patient’s current state of fitness
 Other co-morbidities
 Patient wishes
 Local availability of technology and expertise
 Loco regional involvement and recruitment in clinical trials
Palliative surgical options can be tailored to clinical needs. Various bypass
procedures can be employed to circumvent or drain the biliary system, an effective
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treatment for the jaundiced patient. Less invasive options such as endoscopic or
percutaneous biliary stenting can also be used with either plastic or metal devices.
Stenting with drug eluting covered metal stents is still at an experimental stage.
Chemotherapy has had limited success on this disease. It was not until 2010 that the
first phase III chemotherapy based treatment showed any survival benefit. The ABC-
02 (Advanced Biliary Cancer) was a multi centre UK study that demonstrated an
overall survival benefit using gemcitabine and cisplatin when compared to
gemcitabine alone (Valle et al., 2010b). It currently represents the chemotherapy
treatment standard for unresectable CCA.
The ABC-02 trial became an extension of the ABC-01, a phase II trial that used the
same treatment regime (Valle et al., 2009). Prior to this study, gemcitabine
monotherapy had been one of the most commonly used agents in CCA (Gebbia et
al., 2001). The ABC-02 trial recruited 410 adult patients with unresectable and
histopathology or cytology proven CCA from 37 centres. Patients were randomised
to either of the above two regimes. The study demonstrated that the combination
regime (gemcitabine with cisplatin) improved median overall survival (OS) by 3.6
months (11.7 vs. 8.1 months respectively) when compared to monotherapy with
gemcitabine. The group receiving combination therapy also had improved
progression free survival (PFS) by 3 months (8.0 vs. 5.0 months respectively). The
same investigators have launched two further phase II trials (ABC-03 and ABC-04)
that are investigating the effect of tyrosine kinase inhibitors on patients with
advanced CCA.
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The following table (Table 4) summarises all the phase II and phase III trials published
in the literature to date involving patients with CCA. Table 5 that follows,
summarises the current ongoing phase III trials on patients with CCA.
Study Year of Publication
no of patients
Treatment Type
Phase
Outcome
(Harvey et al., 1984) 1984
17
5-FU
mitomycin
doxorubicin
Palliative
Phase II
PR 31%
SD 41%
(Falkson et al., 1984) 1984
34
5-FU streptozotocin
Methyl-CCNU
Palliative
Phase II
OR 8%
(Ellis et al., 1995) 1995
25
5-FU epirubicin
cisplatin
Palliative
Phase II
RR 40%
(Polyzos et al., 1996) 1996
13
5-FU
mitomycin-C
folinic acid
Palliative
Phase II
RR 23%
MS 22 w
(Jones et al., 1996) 1996
15
paclitaxel Palliative
Phase II
CR 0%
PR 0%
(Patt et al., 1996) 1996
35
5-FU
rIFN alpha-2b
Palliative
Phase II
MS 12m
PR 34%
(Eckel et al., 2000) 2000
30
5-FU
Leucovorin
cyclophosphamide
Palliative
Phase II
MS 7.3 m
(Park et al., 2005) 2005
40
epirubicin, cisplatin,
uracil/tegafur, and
leucovorin
Palliative
Phase II
PR 22.5%
MS 34w
MTTP: 16w
(Ducreux et al., 2005) 2005
58
5-FU
folinic acid cisplatin
Palliative
Phase II
CR 0-4%
PR 7-15%
OR 7-9%
DS 44-46%
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Study Year of Publication
no of patients
Treatment Type
Phase
Outcome
(Park et al., 2006) 2006
43
epirubicin, cisplatin
capecitabine
Palliative
Phase II
PR 40%
MS 8m
SD 23%
(Kim et al., 2006) 2006
29
gemcitabine
cisplatin
Palliative
Phase II
PR 34.5%
OR 34.5%
SD 13.8%
PD 44.8%
MS 11m
(Hong et al., 2007) 2007
32
capecitabine
cisplatin
Palliative
Phase II
PR 41%
CR 0%
SD 9.4%
MTTP 3.5m
MS12.4m
PD 34.4%
(Ciuleanu et al., 2007) 2007
22
OSI-7904L
5-FU
leucovorin
Palliative
Phase II
(Randomised)
SD 0-36%
MTTP 7.4-18w
MS 23.7-29.4w
(Riechelmann et al.,
2007)
2007
75
gemcitabine
capecitabine
Palliative
Phase II
OR 29%
CR 4%
PR 25%
MS 12.7m
SD 49%
MTTP 6.2m
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Study Year of Publication
no of patients
Treatment Type
Phase
Outcome
(Kim et al., 2008) 2008
51
Cisplatin
S-1 (=tegafur
gimeracil
oteracil K)
Palliative
Phase II
OR 30%
CR 4%
PR 26%
SD 42%
PD 18%
MTTP 4.8m
MS 8.7%
(Lee et al., 2008) 2008
39
gemcitabine
cisplatin
Palliative
Phase II
PR 17.1%
SD 28.6%
PD 45.7%
MS 8.6m
MTTP 3.2m
(Meyerhardt et al.,
2008)
2008
33
gemcitabine
cisplatin
Palliative
Phase II
PR 21%
SD 36%
PFS 6.3m
MS 9.7m
OYS 39%
(Yu et al., 2008) 2008
41
gemcitabine
capecitabine
Palliative
Phase II
PR 30.1%
SD 30.1%
MS 10m
MTTP 6m
OYS 40%
(Takezako et al., 2008) 2008
39
Cisplatin
epirubicin
5-fluorouracil
Palliative
Phase II
PR 10%
MS 9.1m
PFS 5.1m
OYS 21%
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Study Year of Publication
no of patients
Treatment Type
Phase
Outcome
(Oh et al., 2008) 2008
15
S-1
oxaliplatin
Palliative
Phase II
PR 6.7%
SD 26.7%
MTTP 1.4m
MOS 3.1m
(Jang et al., 2010) 2010
53
Gemcitabine
oxaliplatin
Palliative
Phase II
OR 18.9%
CR 2%
SD 50.9%
DC 69.8%
PFS 4.8m
MOS 8.3m
(Sasaki et al., 2010) 2010
35
Gemcitabine
S-1
Palliative
Phase II
OR 34.3%
DC 82.9%
MOS 11.6m
MTTP 5.9m
(Bengala et al., 2010) 2010
46
Sorafenib Palliative
Phase II
OR 2%
DC 32.6%
PFS 2.3m
MOS 4.4m
(Lubner et al., 2010) 2010
53
Bevacizumab
erlotinib
Palliative
Phase II
PR 12%
SD 51%
MOS 9.9m
TTP 4.4m
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Study Year of Publication
no of patients
Treatment Type
Phase
Outcome
(Williams et al., 2010) 2010
48
Gemcitabine with
carboplatin
Palliative
Phase II
OR 31.1%.
MPFS7.8
OS10.6
6MS 85.4%
(Gruenberger et al.,
2010)
2010
30
Cetuximab,
gemcitabine
oxaliplatin
Palliative
Phase II
OR 63%
CR 10%
PR 53%
DC 80%
SD 17%
PD 20%
PFS 8.8m
MOS 15.2m
(Karachaliou et al.,
2010)
2010
28
irinotecan
oxaliplatin
Palliative
Phase II
OR 17.9%
MOS 9.2m
MPFS 2.7m
(Lassen et al., 2011) 2011
41
Emcitabine
oxaliplatin
capecitabine
Palliative
Phase II
OR 34%
SD 51%
DC 85%
MOS 12.5 m
MPFS 6.9 m
(Glimelius et al., 1996) 1996
90, (37 biliary)
5FU,
etoposide
leucovorin
Palliative
Phase III
36%↑ QALY
MS 6m
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Study Year of Publication
no of patients
Treatment Type
Phase
Outcome
(Rao et al., 2005) 2005
54
5FU,
etoposide
leucovorin
cisplatin
Palliative
Phase III
MS 9.02-12.03m
RR 15-19.2%
(Takada et al., 2002) 2002
139
5FU
mitomycin-C
Adjuvant
Phase III
No benefit in
treatment arm of
CCAs
(Valle et al., 2010a) 2010
410
Gemcitabine +/-
cisplatin
Palliative
Phase III
Combination arm
↑MOS by 3.6m
and ↑MPFS by 3m
Abbreviations:
DS: Disease Stabilisation, CR: Complete Response, OR: Overall Response, PR: Partial Response, MS: Median
Survival, RR: Response Rate, SD: Stable Disease, m: months, w: weeks, QALY: Quality of life index, MTTP: Median
Time to Progression, PD: Progressive Disease; OYS: One Year Survival; DC: Disease Control; 6MS: 6 month survival;
CR Complete Response
Notes: Some trials do not separate CCA from GB cancers
Table 4 Published clinical trials on chemotherapy for biliary tract tumours
Study Started/No of
Patients
Treatment Type
NCT00262769* May 2005
400
Gemcitabine +/-
Cisplatin
Palliative
NCT00363584 March 2006
360
Capecitabine or
Observation
Adjuvant
NCT00658593 March 2008
320
Gemcitabine +/-
Capecitabine
Palliative
NCT00939848 April 2011
136
Cisplatin/Gemcitabine
+/- Cediranib
Palliative
NCT01149122 January 2009
180
Gemcitabine/Oxaliplatin
+/- Erlotinib
Palliative
NCT01313377 July 2009
190
Gemcitabine/Oxaliplatin
or Observation
Adjuvant
Table 5 Ongoing Phase III studies for patients for biliary tract tumours
* NCT denotes a unique clinical trial registry number (identifier) at clinicaltrials.gov
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Figure 1-2 Management algorithm for cholangiocarcinoma.
*Where magnetic resonance imaging/MRCP is not possible, patients should have contrast
enhanced spiral/helical computed tomography. **Fine needle biopsy or biopsy is ideally avoided
until resectability has been assessed by a specialist surgeon (Khan et al., 2002a).
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1.1.7.3 Experimental therapies
 Photodynamic therapy is gaining favour as a candidate treatment for patients
with non resectable CCA. Photodynamic therapy relies on the favourable
accumulation of photosensitizers, such as porphyrins, in neoplastic or
dysplastic cells. Following local or systemic administration the photosensitizer
is activated by application of nonthermal laser light of an appropriate
wavelength. The photochemical process generates oxygen radicals resulting
destruction of the tissue. Two recent phase II randomised controlled trials
(RCTs) showed that photodynamic therapy improved survival, jaundice and
quality of life, and was well tolerated (Zoepf et al., 2005, Ortner et al., 2003).
Currently there are two phase III trials looking to validate this [NCT01439685,
NCT00869635]†. Although photodynamic therapy can be considered an
alternative to chemotherapy, it remains a treatment confined to large
specialised centres with a particular interest and expertise (Ortner, 2011).
 Another recent and novel approach to treating obstructing biliary tumours
has been the use of drug eluting stents. Paclitaxel has been used with some
reports of success but at an experimental level (Lee, 2009). At least two
phase III trials are investigating the clinical outcomes of this technology
[NCT01413386, NCT00453076].
 Trans-arterial chemoembolization (TACE) with or without drug eluting beads
are another approach championed for their loco regional targeting
† NCT denotes a unique clinical trial registry number (identifier) at clinicaltrials.gov
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properties. A few small pilot studies have recently reported their results but
no phase III trials are currently underway (Kuhlmann et al., 2012).
1.1.8 Cholangiocytes
1.1.8.1 Anatomy
Cholangiocytes are epithelial cells that make up 3-5% of total liver mass. In the adult
human liver they have an estimated total length of approximately 2 km (ANDREWS,
1955).
The biliary tree is formed by a network of ducts that channel bile in one direction of
flow. One way flow is achieved synergistically through simple mechanical pressure
and a constant concentration gradient of bile along the biliary tree.
The most peripheral and smallest ducts are the bile ductules (which have a diameter
of less than 15 μm) that drain into the canals of Herring. Bile ducts then build up in
size ending in the extrahepatic ducts and finally the common bile duct (which is
roughly 5mm in diameter) that drains into the duodenum. Ducts below the order of
the canals of Herring are lined partly by cholangiocytes and partly by hepatocytes.
Ducts that are larger than these are lined only by cholangiocytes. In the human
biliary tree, the smallest orders of bile ducts have a circumference of 4 to 5 cells
while the larger ducts may be lined by up to 40 cholangiocytes.
The microscopic appearance of cholangiocytes differs depending on their anatomical
position. The lower order (more peripheral cholangiocytes) lining the narrower ducts
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are smaller in size and flatter in shape. The cholangiocytes lining the bigger ducts
become larger in size and more columnar in appearance.
Cholangiocytes possess a luminal (apical) and a basolateral surface. They are also
inter-connected by gap junctions that allow the exchange of ions and small
molecules between neighbouring cells (Bode et al., 2002). The apical surface area is
increased fivefold through the presence of microvilli within the bile duct lumen. As
such, cholangiocyte morphology is considered typical of an epithelial cell with
secretory and absorptive properties.
1.1.8.2 Physiology
Apart from morphological heterogeneity cholangiocytes also display physiological
differences according to their anatomical location. This is commonly seen in other
organs too such as the kidney and the small intestine. Transporters, receptors,
enzymes, exchangers, and channels are expressed in different amounts (both on the
apical and basolateral membranes) in fitting with how far down the biliary tree a cell
is located. For instance, animal studies show that the ABAT transporter (the apical
Na+-dependent bile acid transporter which allows internalization of bile acids in
cholangiocytes and which responds to bile acids with changes in cholangiocyte
secretory processes) is expressed in large bile ducts but not in small ones (Alpini et
al., 1997).
The different protein expression of proteins in cholangiocytes serves in regulating
the transepithelial movement of ions, solute, and water. The involvement of
transporters, exchangers and channels in this process results in the formation of bile,
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suitable for secretion into the gut lumen. These are regulated by heterogeneity in
receptor expression which is acted upon by hormones, regulatory peptides,
neurotransmitters, and by bile-borne regulatory factors (Johnson, 2006).
1.1.9 Selective (targeted) drug delivery
In vivo targeted drug therapy confers two potential benefits:
1. It results in the delivery of higher concentrations of drug to an intended target
maximising its effect and in doing so reducing the total amount needed to
administer.
2. It minimises the impact of these drugs on areas other than the intended
destination (non-target sites). Many of the challenges facing current anticancer
therapies are related to the toxic side effects of the drugs employed.
Gastrointestinal disturbances, nausea, myelosuppression and neuropathy for
instance arecommon and serious problematic side effect of many cytotoxic drugs
used in the treatment of solid tumours. If the physical presence of these drugs in
non cancerous tissues could be reduced then the potential side effects could be
minimised.
Attempts to achieve selective drug delivery have been pursued through the use of
various means.
If the target is a solid tumour, agents can be delivered to a particular anatomical
location. One way this can be achieved is by the injection of a drug directly into an
identifiable tumour, if necessary under image guidance.
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Another anatomical strategy is capitalising on tumour blood supply. An example that
is already in practice is the use of TACE (trans arterial chemo embolisation) to treat
hepatomas. Hepatomas derive the majority of their blood supply from branches of
the hepatic artery. The feeding vessels can be identified and accessed radiologically
where agents can be delivered.
1.2 Experimental models to study the effect of chemotherapy in CCA
1.2.1 In vitro preclinical models
Experimental model systems have been central to providing basic and preclinical
insights into many cancers. The usual starting point in assessing efficacy of
chemotherapy agents is by investigating the effects of the agents under investigation
on cultured cell lines in an in vitro setting. In vitro models are the first step in rational
drug discovery and development but serve only the purpose of selecting compounds
for secondary, more comprehensive, in vivo testing. This approach is employed by
the largest preclinical screening scheme to date, the NCI-60 project (the US National
Cancer Institute (NCI) 60 human tumour cell line anticancer drug screen)
(Shoemaker, 2006). This project which started in the 1980s and is still running uses a
panel of 60 cell lines derived from the most common tumours (leukaemia,
melanoma, non small cell lung, central nervous system, colorectal, ovarian, renal
prostate and breast cancer). To date, these cell lines have been exposed to over
100,000 different agents using a standardised automated high throughput protocol.
Cell culture studies have several advantages that have established them as a starting
point in cytotoxicity testing. They are relatively inexpensive; they are straightforward
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and can be performed relatively quickly. They are carried out in a controlled
environment and can easily be standardised and reproduced.
Critics argue that they fail to take into account the microenvironment of malignant
cells, as they cannot mimic the complexities of drug delivery, metabolism and
excretion found in a complete organism. Furthermore they can have a substantially
different genome to the disease they are used to represent.
The low incidence of CCA is reflected in the number of cell lines developed for this
disease. There are currently only a handful of CCA and immortalised biliary
epithelium cell lines available, most of which were developed at academic
institutions. Some major cell line collections such as the European Collection of Cell
Cultures (ECACC) and the American Type Culture Collection (ATCC) do not have CCA
or cholangiocyte cell lines available (ECACC, 2012, ATCC, 2012).
1.2.2 In vivo preclinical animal models
A reliable orthotopic animal model for CCA has not been developed yet. Several
approaches have been employed.  Early attempts used animal exposure to a
combination of parasitic infection and systemic carcinogenic agents. More recent
approaches have been to use local or systemic administration of toxins to induce
CCA development (Yeh et al., 2004). Another approach has been the direct injection
of CCA cell lines into the liver (Sirica et al., 2008).
Farazi et al, described a murine model where p53 mutant mice were subjected to
chronic exposure to intermittent intra-peritoneally instilled toxin (carbon
tetrachloride (CCl4)) (Farazi et al., 2006). The exposure induced a state of chronic
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inflammation in the biliary tree and the mice eventually developed intrahepatic CCA.
However, their model had a long latency time (4 months of treatment with some
mice developing CCA a few weeks after the end of exposure). In addition many mice
developed cirrhosis and a variety of other tumours including sarcomas, lymphomas,
and hepatocellular cancers. Most mice succumbed to the other tumours.
Sirica et al, presented an orthotopic animal model claimed to be more “patient like”.
Rats were inoculated with a rat CCA cell line (BDEneu or BDEsp) by direct injection of
cultured cells into the biliary tree or liver (Sirica et al., 2008). They reported a 100%
success rate within 20 days post inoculation with BDEneu in the liver injected rats.
Bile duct injected rats were less successful in growing CCA with a success rate of 56%
when the BDEsp cell line was used. This model also involved suture ligation of the
bile duct, to emulate the cholestasis experienced by human patients and some rats
developed extrahepatic metastatic disease, whilst establishing the model takes 3 to
4 weeks. However, despite this model’s apparent advantages, the only publications
come from the research group that developed it (last date of PubMed search:
February 2012).
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1.3 Research aims
This study set out to:
1. To investigate the effect of various chemotherapeutic agents either alone or
in combination in the treatment of cultured cholangiocarcinoma cells.
2. To investigate the effect of adding PK11195 as a sensitising agent to enhance
the action of various chemotherapeutic agents in cultured
cholangiocarcinoma cells.
3. To analyse the proteome of a panel of cholangiocarcinoma cell lines and to
assess the presence of potential biomarkers and therapeutic targets.
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2 Verification of cell lines by immunohistochemistry
2.1 Introduction
In vitro cell line testing is a convenient first step for cytotoxic drug evaluation;
however, this experimental method comes with several limitations (see chapter
1.2.1). A well-recognised problem in cell line use is their misidentification or
contamination with other cell types. Numerous studies have estimated that up to
36% of cell lines used in research are of a different origin or species to that claimed
(Nature, 2009, Masters et al., 2001).
Immunostaining is a technique often employed in clinical practice to determine the
origin of tissue specimens. The histopathological diagnosis of cancers can often pose
a clinical challenge especially for metastatic disease of unknown origin. In addition,
diagnostic dilemmas can arise where adjacent structures can be similar. A common
diagnostic problem particular to HPB malignancies is the differentiation of
cholangiocarcinoma from hepatocellular cancer. Immunohistochemistry is a valuable
tool in such settings as it can help identify the tissue of origin which in turn can assist
in guiding what form of treatment a patient should receive, especially when
optimising chemotherapy (Bateman and Hubscher, 2010).
Immunostaining was therefore performed to the cell lines used in this study, in an
attempt to prove their epithelial origin but also to ensure that they expressed a
profile consistent with tissue of biliary origin. Cells were stained for cytokeratin 7,
cytokeratin 19 and epithelial membrane antigen.
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Cytokeratins are proteins of keratin-containing intermediate filaments found in the
cytoskeleton of cells with epithelial tissue origin and form the bedrock of the
immunohistochemical evaluation of tumours (Jain et al., 2010).
Cytokeratin 7 (CK7) is a basic type II cytokeratin found on many glandular and
transitional epithelia. It is encoded by the KRT7 gene and is usually present in
adenocarcinomas of the lung, breast, ovary, serous and endometrial tumours,
uterine cervical tumours, transitional cell carcinoma of the bladder, biliary
epithelium and cholangiocarcinoma. It is not found on hepatocytes and
hepatocellular carcinoma and it is hence used to differentiate HCC from CCA (Dennis
et al., 2005).
Cytokeratin 19 (CK19) is a type I keratin protein that in humans is encoded by the
KRT19 gene. It is expressed in most epithelial cells and many tumours such as
prostate (Pu et al., 2007) and breast cancer (Sakaguchi et al., 2003). Cholangiocytes
and CCA cells usually express CK19, unlike hepatocytes and HCC so it is used in
conjunction with CK7 to differentiate between the two (Bateman and Hubscher,
2010).
Epithelial membrane antigen (EMA) also referred to as Mucin 1, cell surface
associated (MUC1) and polymorphic epithelial mucin (PEM) is expressed by most
epithelial cancers (Davidson et al., 1988). In contrast to hepatocellular cancer, it is
often expressed by cholangiocarcinoma cells (Bonetti et al., 1983, Haratake and
Hashimoto, 1995).
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2.2 Methods
2.2.1 Immunostaining with CK7, CK19 and EMA
Cells were grown to sufficient quantities in tissue culture flasks as described
elsewhere (see chapter 3.2.1). Cells were then lifted with trypsin and placed on an 8
well glass chamber slide (LabTek, Cat no 177402). Four replicates of the same cell
passage were used for each cell line. Cells were allowed to culture in medium
overnight in order to adhere to the chamber slide surface (for relevant medium and
recipe, see section 3.2.1).
On removal from the incubator, one slide was set aside for haematoxylin and eosin
(H&E) staining. Three slides were exposed to cold (4oC) paraformaldehyde (4%
concentration) for 10 minutes to ensure fixation. The paraformaldehyde was
removed and cells were exposed to a few drops of blocking agent for 10 minutes
(Power Block™ Universal Blocking, cat no HK085-5K, Biogenex). Slides were then
washed with PBS twice. Two drops of antibody (CK7, CK19 and EMA) were added to
the slides which were then allowed to stand overnight at 4oC. The silicon chamber
separators were dissected using a sharp surgical scalpel on the following day. Slides
were then exposed to pre prepared secondary anti mouse antibody (1:300 dilution)
(Cy3 conjugated Affinipure F(ab’)2 Fragment donkey Antimouse IgG, cat no. 715-166-
150, Jackson immunoresearch labs, West Grove, PA) and left for 45 minutes in a
horizontal position in a dark cupboard. Slides were then placed in a slide rack and
washed twice by submersion in PBS with DAPI. Slide covers were attached using
water based glue.
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2.2.2 Staining with haematoxylin and eosin (H&E)
One slide for each cell line was reserved for H&E staining. Following fixation, slides
were washed with water and covered with haematoxylin for 5 minutes. They were
then washed again with water and covered with eosin for 3 minutes. After washing
in water again, a cover-slip was attached using aqueous glue.
2.3 Results
Slides were viewed and images were captured at X 20 and X 40 magnification using
an inverted fluorescence microscope (Olympus IX-71).
2.3.1 H69
Figure 2-1 H69 cells stained with H&E (x40 magnification)
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Figure 2-2 H69 cells stained with EMA (x40 magnification)
Figure 2-3 H69 cells stained with CK7 (x40 magnification)
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Figure 2-4 H69 cells stained with CK19 (x40 magnification)
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2.3.2 HUCC
Figure 2-5 HUCC-T1 cells stained with Haematoxylin and Eosin (x20 magnification)
Figure 2-6 HUCC cells stained with EMA  (x40 magnification)
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Figure 2-7 HUCC-T1 cells stained with CK7 (x40 magnification)
Figure 2-8 HUCC cells stained with Ck19 (x40 magnification)
Verification of cell lines by immunohistochemistry
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2.3.3 SkChA1
Figure 2-9 SkChA-1 cells stained with Haematoxylin and Eosin (x40 magnification)
Figure 2-10 SkChA-1 cells stained with EMA (x40)
Verification of cell lines by immunohistochemistry
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Figure 2-11 SkChA1 cells stained with CK7 (x40 magnification)
Figure 2-12 SkChA1 cells stained with CK19 (x40 magnification)
Verification of cell lines by immunohistochemistry
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2.3.4 M213
Figure 2-13 M213 cells stained with H&E (x20 magnification)
Figure 2-14 M213 cells stained with EMA
Verification of cell lines by immunohistochemistry
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Figure 2-15 M213 cells stained with CK7 (x40 magnification)
Figure 2-16 M213 cells stained with CK19 (x40 magnification)
Verification of cell lines by immunohistochemistry
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2.4 Discussion
The objective of this section of the study was to establish whether or not the panel
of cell lines to be used was consistent with having originated from the biliary tree. All
cell lines tested positive to CK7, CK19 and EMA which suggests that this is true. They
were therefore deemed relevant to the subject of study. These results are consistent
with previously published data on these cell lines (Harnois et al., 1997, Yoshikawa et
al., 2009).
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3 Cell line cytotoxicity assays
3.1 Introduction
3.1.1 Cytotoxicity testing
Cytotoxicity testing is based on one or more mammalian cell lines cultured under
conditions where they are actively growing and dividing. Cells are grown in a
microtitre plate (such as a 96 well plate) and the rate of multiplication and growth is
quantified indirectly by formation of a colour, the intensity of which is directly
proportional to the cell volume present. A variety of experiments can be employed
but a commonly used method is to compare the rate of proliferation of a cancer cell
line in the presence and absence of the test substance, usually after a specified time.
Ideally several different cancer cell lines should be used to assess selectivity
(Houghton et al., 2007). The two most established cytotoxicity assays are the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and the
Sulforhodamine B (SRB) assay. The MTT assay was developed in 1986 and relies on
mitochondrial reduction of the MTT (which has a yellow colour) to a formazan (deep
purple). The formazan can be then quantified through spectrophotometry
measurement in an automated plate reader.
The MTT assay’s main limitation arises from its dependence on mitochondrial
function. Factors affecting their activity can influence the assay outcome. Examples
such as variations in cellular levels of NADH and glucose can mimic the effect of
cytotoxics.
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The SRB assay on the other hand does not rely on mitochondrial function. It is more
sensitive, simple, reproducible and more rapid than the MTT assay and gives better
linearity, a good signal-to-noise ratio and has a stable end-point that does not
require a time-sensitive measurement (Keepers et al., 1991). A detailed explanation
of the SRB assay is described further down (see section 3.2.4).
Assessment of cytotoxicity to CCA cell lines was performed in vitro using the SRB
assay. Three separate cell lines, each representing a different form of CCA, were
exposed to agents either alone or in combination. The same cytotoxic agents were
also tested in the presence and absence of PK11195.
3.1.2 Cytotoxic agents
3.1.2.1 Gemcitabine
Gemcitabine (20-20 difluorodeoxycytidine) is a water soluble intravenously
administered chemotherapeutic agent developed in the late 1980s. It is a nucleoside
analog that functions as a pyrimidine antimetabolite by imitating the structure of the
natural nucleoside deoxycytidine. It is incorporated into the end of the elongating
DNA strand instead of deoxycytidine and works as a masked chain terminator in DNA
synthesis. Damaged DNA then triggers an apoptotic pathway (Plunkett et al., 1995).
In the UK, it is currently licensed for the treatment of several solid cancers and is
marketed under the brand name of Gemzar. Gemcitabine is licensed to be used
alone or in combination with other agents in the treatment of metastatic pancreatic
cancer, locally advanced or metastatic non-small cell lung cancer, advanced bladder
cancer and metastatic breast cancer (BNF, 2012). In the US, gemcitabine has further
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approval in the treatment of advanced ovarian cancer (FDA, 2012). In the European
Union, Elli Lilly held the patent on gemcitabine until March 2009 after which it
became available in its generic form by non-proprietary manufacturers.
Gemcitabine, in combination with cisplatin has recently been shown to be effective
in the treatment of patients with cholangiocarcinoma and represents the current
treatment of choice (see section 1.1.7.2) (Valle et al., 2010b).
Gemcitabine is generally well tolerated. The most common side effects are mild
gastro-intestinal disturbances, musculoskeletal pain, influenza-like symptoms and
rashes. Less frequently patients can suffer from renal impairment and pulmonary
toxicity.
3.1.2.2 Cisplatin
Cisplatin (also referred to as cisplatinum, or cis-diamminedichloroplatinum(II) (CDDP)
chemical formula: Cl2H6N2Pt) is a widely used, intravenously administered, platinum-
based chemotherapy agent. It has a molar mass of 300g/mol.
Although as a compound it was first described in 1845, its biological activity was not
recognised until 1965 (Rosenberg et al., 1965). It received its first FDA licence for
human use in 1978. Today, it is used either alone or in combination with other
agents to treat patients with a variety of cancers, including sarcomas, lymphomas,
germ cell tumours and certain carcinomas (such as small cell lung and bladder
cancer). It was the first member of the platinum based class of anti-cancer drugs
which now also includes carboplatin and oxaliplatin.
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Cisplatin works by crosslinking DNA in several different ways, interfering with mitotic
cell division. DNA that has been damaged then triggers DNA repair mechanisms,
which in turn force the cell to an apoptotic pathway.
Cisplatin is toxic, and can cause nephrotoxicity, ototoxicity, peripheral neuropathy,
hypomagnesaemia and myelosuppression.
Cisplatin, in combination with gemcitabine has recently been shown to be effective
in the treatment of patients with cholangiocarcinoma (see section 1.1.7.2) (Valle et
al., 2010b).
3.1.2.3 Etoposide
Etoposide was first synthesised in 1966, and was first granted FDA approval in 1983
(Hande, 1998). It is a chemotherapeutic agent that can be administered orally or by
slow intravenous infusion. It is used either alone or in combination with other agents
and is licensed for use in small cell carcinoma of the bronchus, the lymphomas and
testicular cancer (BNF, 2012).
Etoposide’s mechanism of action is by inhibiting type II topoisomerase, an enzyme
responsible for unwinding DNA. This inhibition results in breakage of DNA strands.
Damaged DNA then triggers apoptosis.
Toxic effects of etoposide include alopecia, myelosuppression, nausea, and vomiting.
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3.1.2.4 Fluorouracil
Like gemcitabine, fluorouracil (commonly referred to as 5-FU), belongs to a class of
chemotherapeutic agents called antimetabolites. Antimetabolites are incorporated
into newly manufactured DNA activating apoptotic pathways.
5-FU was first synthesised in 1957 and it is an intravenously administered drug.
However, it is also available as capecitabine, an oral prodrug that is converted to 5-
FU in the tissues (Shirasaka, 2009). It is licenced for use in the treatment of a number
of solid tumours, including gastro-intestinal tract cancers and breast cancer (BNF,
2012).
Toxicity is unusual, but may include myelosuppression, mucositis, and rarely a
cerebellar syndrome. On prolonged infusion, a desquamative hand–foot syndrome
may occur.
3.1.2.5 PK11195
PK11195 (or 52028 RP; 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-
isoquinoline carboxamide) is a peripheral benzodiazepine receptor ligand. It is a
synthetic molecule that binds to the mitochondrial benzodiazepine receptor. It can
antagonize both Bcl-2 proper and Bcl-XL function thereby stopping the inhibition of
apoptosis (Hirsch et al., 1997). Bcl-2 proper and Bcl-XL belong to the Bcl-2 family of
proteins.
Addition of PK11195 to CCA cell lines (Egi-1 and Tfk-1) reduced the threshold for
ultraviolet, radiation and chemotherapy (etoposide and 5FU) induced apoptosis
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(both in vivo and in vitro) (Okaro et al., 2002). Furthermore, in some cell types,
PK11195 alone is able to induce apoptosis (Santidrián et al., 2007). PK11195 has not
been tested before with the CCA cell lines used in this experiment. Furthermore, its
potentiating effects have not been tested  in combination therapies.
Oral and intravenous administration of incremental doses of PK11195 to healthy
volunteers was well tolerated without any significant side effects (Ferry et al., 1989).
3.2 Materials and methods
3.2.1 Cell lines
Several human derived CCA cell lines were used, each representing a subtype of the
disease. All cell lines were of the adherent type. Acquisition of cell lines proved to be
a challenge due to the scarce availability of CCA cell lines. Most can only be acquired
through non commercial sources. Indicative of this is that the European Collection of
Cell Cultures (ECACC), the largest of its kind in Europe and possessing more than
1,100 cell lines, does not have offer a CCA cell line. The American Type Culture
Collection (ATCC), an equivalent organisation in the United States does not have any
CCA cell lines in its collection either.
3.2.1.1 HUCC T1
HUCC-T1 is derived from the ascitic fluid of a 56 year old male patient from Japan
(Miyagiwa et al., 1989). The patient died 2 months after the cell line was established
from an intra hepatic CCA. HuCC-T1 cells, kindly provided by Dr. Giles Smith
(University College London) were routinely cultured in RPMI 1640 (Sigma-Aldrich,
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Dorset, UK), supplemented with 10% (volume to volume) heat inactivated foetal calf
serum (FCS), 2 mM L-Glutamine (Gibco-Invitrogen, Paisley, UK) streptomycin and
penicillin.
3.2.1.2 SK-ChA-1
SkChA1 is derived from the ascitic fluid of a 47 year old female patient in Germany
(Knuth et al., 1985). The patient died one month after the cell line was established of
an extra hepatic CCA. Sk-ChA-1 cells were also provided by Dr. Giles Smith and were
cultured in the same fashion and medium as HUCC-T1 cells.
3.2.1.3 SG231
SG231 is a cholangiocarcinoma cell line, however, its original anatomical location has
not been made clear by the authors (Storto et al., 1990). SG231 were also provided
by Giles Smith and were cultured in Dulbecco’s Modified Eagle Medium (DMEM -
Gibco 21969) supplemented with 10% heat inactivated FCS. To a 500 ml bottle of
DMEM the following were added: 5 ml of L-Glutamine, 5 ml of NEAA (x100, Gibco
11140) and 0.5 ml of gentamicin (Sigma G1272).
SG231 cells were sub-cultured using 0.5% trypsin/EDTA (Sigma-Aldrich).
3.2.1.4 KKU-M213
KKU-M213 is an intrahepatic adenosquamous cholangiocarcinoma cell line derived
from a 58 year old male patient from Thailand. The cells were kindly donated by Dr
Temduang Limpaiboon and Ruethairat Sriraksa from the Liver Fluke and
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Cholangiocarcinoma Research Center, Faculty of Medicine, Khon Kaen University,
Thailand.
KKU-M213 cells were cultured in the same medium as HUCC-T1 cells.
3.2.1.5 H69
H69 cells are a cell line derived from normal human intrahepatic cholangiocytes and
were produced using retroviral transduction of SV40 and were also provided by Dr.
Giles Smith (Grubman et al., 1994).
H69 cells were cultured in medium, the recipe for which was kindly provided by Dr.
Sharon DeMorrow from the Texas A&M Health Science Center. The medium was
made up with the following: DMEM with high glucose (Invitrogen, Cat No.
11095098), DMEM/F-12, (Invitrogen, Cat No. 11330057), 50ml Foetal bovine serum
(Invitrogen, Cat No. 16000044), Penicillin/Streptomycin (Invitrogen, Cat No.
15140155), Adenine (Sigma, Cat No. A2786), Insulin (Sigma, Cat No. I2643),
Epinephrine (Sigma, Cat No. E4250), 3,3 Triiodo-l-thyronine (Sigma, Cat No. T6397),
Epidermal Growth Factor (Millipore, Cat No. 01-102), Hydrocortisone (Sigma, Cat No.
H0888).
Since the H69 cell line represents an immortalised normal cholangiocyte, it was not
used in chemotherapy experiments. It was used in experiments described later (see
section 4.2.2) as a reference for comparison.
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3.2.2 Cell storage and culture
All cell lines were stored in liquid nitrogen tanks (-196oC), at a volume of roughly 1
million cells aliquot per cryovial. Cells were suspended in 1mL of the appropriate
medium containing 20% heat inactivated FCS and 10% DMSO prior to freezing.
Revival of cells from liquid nitrogen storage was performed by quick thawing in a
37oC water bath. Thawed cells were washed in 10 ml of medium, harvested by
centrifugation for 5 minutes at 1000 g and were then transferred to 25 cm2 culture
flasks containing fresh culture medium.
Cell culture was carried out in Class 2 laminar flow cabinets (Scanlaf Mars) and all
materials were sterile and disposable. All cell lines were adherent and were grown as
monolayers in plastic tissue culture flasks incubated in a humidified atmosphere of
5% CO2 at 37oC. Cells were regularly checked and once they had covered the surface
available for growth (to approximately 80% confluence) were sub-cultured in a 1:3
split. The smallest culture flasks used were 25cm2whilst large volumes were cultured
in triple layer flasks providing 500cm2 of surface area for growth. Exhausted media,
due to cell metabolism and natural degradation of ingredients was changed
periodically as required, to ensure optimal growing conditions.
3.2.3 Cell counting
Cell numbers and concentrations were calculated using an improved Neubauer
haemocytometer visualised through an inverted microscope. The chamber was
loaded with a 10µl volume of medium containing suspended cells mixed with equal
volume of trypan blue and covered with a disposable glass cover slip. Trypan blue is
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a stain that selectively transverses cell membranes of dead cells. It hence allows
identification of viable cells via dye exclusion.
3.2.4 The sulforhodamine B assay
Growth characteristics and sensitivity of CCA cell lines to chemotherapy agents were
measured by using the SRB assay as described in 1990 by Skehan et al (Skehan et al.,
1990). The SRB assay remains one of the most commonly used methods for in vitro
cytotoxicity screening.
Sulforhodamine B is a bright pink protein dye. The assay relies on the ability of SRB
to bind to the basic amino acid residues of cells fixed with TCA, in an electrostatic
and pH dependent manner. In mildly acidic conditions, SRB binds to basic amino
acids and in mild basic conditions it dissociates. This property can be exploited by
extracting SRB and then solubilising it for colorimetric measurement. Quantification
of the dye directly relates to the amount of protein present, which is linearly
proportional to the number of cells present. As such SRB acts as a surrogate
endpoint for cell mass at the end of the cell growth experiment.
The assay has several advantages: it is practical, it is not destructive, treated culture
plates remain indefinitely stable at several steps and it is relatively low cost. As such
it is considered an appropriate and sensitive assay to measure drug-induced
cytotoxicity even at large-scale application. It is worth mentioning that the SRB assay
is the method of choice for the NCI-60 project - a high-flux anticancer drug screening
program that has tested the activity of several hundred thousand compounds on a
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panel of 60 cancer cell lines (Monks et al., 1991). None of these cell lines are CCAs
(Sharma et al., 2010).
Cells suspended in 100µl of growth medium per well, were added at the relevant
inoculation densities (see section 3.2.5) to 96 well microtitre plates and left to
adhere for 24 hours. At this stage the medium was aspirated and replaced with the
agent(s) under investigation at the relevant concentration, diluted in 200µl of fresh
growth medium and left to incubate for two cell cycles. Each agent was routinely
prepared and tested at five to six concentrations ranging from 1x10-4 to
1x10-9Mwith 10-fold dilutions in between. Each concentration was replicated three
to four times on the same plate. Experiments were replicated identically on three
separate 96 well plates, carried out on different days thus givng a total of at least 9
replicates for each experiment.
Figure 3-1 Typical 96 well plate layout for cytotoxicity testing
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The plates were read on a Tecan SPECTRAFLUOR plus plate reader which gave the
optical densitometry (OD) of each well. The automatic plate reader had the following
parameters set: a 10 second orbital shake, followed by four random location
absorbance readings per well, at a wavelength of 492nm.
Cell survival was calculated using the mean optical density (OD) of treated cells as a
percentage of the mean OD of controls, using the following equation:
Cell survival (%) =
Dose response curves were generated using commercially available statistical
software (Graphpad Prism 5.0). Two-way analysis of variance (ANOVA) with
Bonferoni post hoc tests were used to compare different concentrations and
regimes. The methodology for statistical analysis was discussed with a medical
statistician (Dr Nicos Middleton, PhD, Harvard School of Public Health).
3.2.5 Growth characteristics
The SRB assay should ideally be performed after cells have been exposed to a
cytotoxic for about 2 cell cycles (Skehan et al., 1990). For practical reasons,
inoculation densities that would produce a cell cycle of about 48 hours were sought.
To establish the ideal inoculation densities which would achieve these parameters, a
separate experiment was carried out. Incremental numbers of cells, ranging from
1,000 cells per well to 80,000 cells per well, were added to 96 well plates and
incubated for up to 5 days. Every 24 hours one plate was sacrificed, and the SRB
assay was performed. As optical density is directly proportional to the number of
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cells present, the results were plotted on a graph and the cell doubling time was
determined for each inoculation density.
3.2.6 Cytotoxicity assays
Cytotoxicity assays were carried out using the SRB protocol as described in
paragraph 3.2.4.
3.2.6.1 Preparation of cytotoxic agents
Although the risks of occupational low level exposure to cytotoxic agents has not
been determined, all agents were treated as hazardous materials. All cytotoxics were
prepared in a safety laminar flow cell culture cabinet to ensure maximum sterility
and surfaces were wiped with 70% alcohol afterwards.
3.2.6.1.1 Gemcitabine preparation
Gemcitabine has a molar mass of 263.198 g/mol. It was acquired as a stock liquid
solution with a concentration of 38mg/ml from the Hammersmith Hospital pharmacy
and stored at -80oC until use (Humbert et al., 2010). It was diluted to concentration
of 1x10-4 to 1x10-9 mMwith cell culture medium prior to in vitro use.
Figure 3-2 Structure of gemcitabine
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3.2.6.1.2 Cisplatin preparation
Cisplatin comes in an off-white to orange powder form and must be solubilised prior
to experimental use in cell culture (Enzo Life Sciences (UK) LTD, Exeter, Product code:
ALX-400-040-M050). It is sparingly soluble in water and insoluble in ethanol.
Although readily soluble in DMSO, a commonly used solvent, DMSO substitutes the
chloride ligands resulting in a variety of different compounds (Kerrison and Sadler,
1977). This reduces the effect of cisplatin (Gebel and Koenig, 1999).
Hence, cisplatin was solubilised in NNDMF (dimethyl formamide) as suggested by the
product distributor. Ten milligrams of cisplatin were added to 1.333ml of NNDMF,
resulting in a 25mM concentration. Solutions were then made up for 1x10-4 to 1x10-9
mMwith cell culture medium.
Figure 3-3 Cisplatin Structure
3.2.6.1.3 Etoposide preparation
Etoposide has a molar mass of 588.557 g/mol and comes as a white powder (Sigma
Aldrich, UK, Prod code: E1383). Ten milligrams of etoposide were solubilised in 0.34
ml of DMSO to create a stock solution. DMSO was used as a solvent in accordance
with the product literature and previous publications (Olmos et al., 2004, Joel et al.,
1995). No evidence was found to suggest that DMSO affects the potency of
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etoposide in a similar manner to cisplatin. Solutions were then made up for 1x10-4 to
1x10-9 mMwith cell culture medium.
Figure 3-4 Structure of etoposide
3.2.6.1.4 5 FU preparation
5-Flurouracil has a molar mass of 130.077 g/mol (Sigma Aldrich, Prod Code:F6627). It
is water soluble so it was made up to concentrations of 1x10-4 to 1x10-9 mM with cell
culture medium (Krishnaiah et al., 2002).
Figure 3-5 Structure of 5-FU
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3.2.6.1.5 PK11195 preparation
PK11195 has a molar mass of 352.856 g/mol (Sigma Aldrich UK, Prod Code: C0424). It
was solubilised in DMSO and then diluted to 1x10-4 to 1x10-9 mMwith cell culture
medium (Ryu et al., 2005). No published evidence was found to suggest that DMSO
affects PK11195 in a similar manner to cisplatin. DMSO, a colourless liquid is
generally considered safe and non toxic (Brown et al., 1963). DMSO is used as a
topical analgesic and anti inflammatory and is championed as a ‘natural healer’, to
the extent that several ‘self-help’ books in popular culture have been published
(Walker, 1993, Walters, 1993). However, at high concentrations above 10%, DMSO
can be cytotoxic in cell culture (Da Violante et al., 2002).
Figure 3-6 Structure of PK11195
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3.2.6.2 Combination chemotherapy
Cells were exposed to monotherapy and all different permutations of combination
chemotherapy. The agents used in combination chemotherapy were used
simultaneously reflecting usual clinical practice:
Gemcitabine and cisplatin
Gemcitabine and etoposide
Gemcitabine and fluorouracil
Cisplatin and etoposide
Cisplatin and fluorouracil
Etoposide and fluorouracil
3.2.6.3 Chemotherapy in combination with PK11195
To determine whether or not PK11195 affected the sensitivity of cell lines to
chemotherapy agents, each single chemotherapeutic agent was assessed in
combination with PK11195. Cell lines were exposed to a chemotherapy regime
alone, PK11195 alone or a combination of PK11195 plus agent at the same
concentrations. Furthermore combination chemotherapy regimes were also tested
in the presence and absence of PK11195.
The concentrations ranged from 1x10-4 to 1x10-9 M. Four wells of each concentration
were used and experiments were replicated 3 times, giving a total of at least 12
replicates per experiment. More details on the protocol are given in chapter 3.2.4.
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3.2.7 BCL-2 expression
3.2.7.1 RNA extraction
Cells (H69p35, M213p36, SkChA1p58 and HUCCp99) were grown to sufficient
quantities as described previously (section 3.2.1). Cells were lifted and washed in
PBS and pellets were stored at -80oC. RNA extraction and purification was performed
using the RNeasy Mini Kit (Qiagen, Cat No. 74104). The protocol used was the HCSG
modification to the published protocol by Qiagen, as outlined below:
A cell pellet was added to 600 µl of RLT buffer and passed through a QIA shredder
column (Qiagen, Cat No. 79654) by centrifuging for 2 minutes at full speed. The flow-
through was kept and 600µl of 100% EtOH was added and mixed by pipetting. The
mixture was transferred to an RNeasy spin column in a 2 ml tube at 700µl at a time
and centrifuged at maximum speed for 15 seconds (>8,000g). The flow through was
discarded, 500µl of RPE buffer was added and centrifuged again at maximum speed
for 15 seconds. The flow through was discarded and a 700µl of RWI buffer was
applied to the column and centrifuged for 15 seconds at maximum speed. The flow
through was again discarded and 500µl of RPE buffer was applied and centrifuged
again for 15 seconds at maximum speed. The flow through was discarded and 500µl
of RPE buffer was applied and centrifuged again for 2 minutes at 8,000g. The flow
through was discarded and the columns were spun for 1 minute at full speed to
collect any remaining buffer, which was then discarded. The samples were collected
by applying two successive aliquots of 50µl of water and spun for 1 minute. The flow
through was collected and the columns discarded.
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3.2.7.2 RNA quantification
RNA was quantified using a Nanodrop ND 1000 spectrophotometer and samples
were stored in 50µl aliquots at -80oC.
3.2.7.3 cDNA conversion
cDNA conversion was carried out using the ‘High Capacity cDNA Reverse
Transcription Kit’ (Invitrogen, Applied Biosystems, Cat No. 4368814). A mastermix
was made up in advance using the following recipe: 10X Reverse Transcription Buffer
2µl per reaction, 25X dNTPs 0.8µl per reaction, 10X random primers 2µl per reaction
and MultiScribe™ Reverse Transcriptase 1 µl per reaction making a total of 5.8µl of
mastermix per reaction.
Each mastermix aliquot of 5.8µl was added to 14.2µl of RNA and added to a well on
the reaction plate. RNA was diluted if necessary in advance using H2O, to achieve the
recommended range by the manufacturer between 0.002 and 0.2 μg/μL. The plate
was covered, briefly centrifuged and placed on the thermal cycler. The settings used
for the reaction were as follows: 10 minutes at 25oC, 120 minutes at 37oC, 5 minutes
at 85oC and then at 4oC until discontinuation. The plate was stored at -4oC until the
qrt-PCR reaction.
3.2.7.4 TaqMan Assay
BCL-2 expression was assessed using a TaqMan Gene Expression Assay (Applied
Biosystems, Assay ID: Hs00236329_m1). β- actin (Applied Biosystems) was selected
to act as an endogenous control. Each reaction was performed in duplicate.
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The reaction mixture was made up according to the following recipe: 20✕ TaqMan
Gene Expression Assay 1µl, 2✕ TaqMan Gene Expression Master Mix 10µl, cDNA
template 4.0 µl and RNase-free water 5.0 µl per reaction. A MicroAmp 96 well
reaction plate was used (Applied Biosystems, Cat No. 4306737) and each reaction
was loaded into a separate well. The plate was covered, briefly centrifuged and
loaded into the thermal cycler (Applied Biosystems 7900HT Fast Real-Time PCR
System). The conditions were set as follows: 10 minutes at 95oC followed by 40
cycles at 95oC for 15 seconds and 60oC for 1 minute.
3.2.7.5 Analysis
Data analysis was performed using SDS 2.4, supplied by Applied Biosystems on CD-
ROM as part of the TaqMan Assay kit.
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3.3 Results
3.3.1 Growth characteristics
The mean values of the absorbance for each cell line at incremental inoculation
densities are depicted in the figures below.
3.3.1.1 SkChA1
The target of a 48 hour doubling time was best served by an inoculation density of
20,000 cells per well (calculated by non-linear regression as 50.60 hours).
Figure 3-7 SkChA1 growth characteristics
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3.3.1.2 HUCC T1
The target of a 48 hour doubling time was best served by an inoculation density of
20,000 cells per well (calculated by non-linear regression as 45.71 to 53.97 hours).
Figure 3-8 HUCC growth characteristics
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3.3.1.3 KKU M213
The target of a 48 hour doubling time was best served by an inoculation density of
10,000 cells per well (Calculated by non-linear regression as 41.80 to 57.22 hours).
Figure 3-9 Growth Characteristics KKU M213 cells
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A summary of the inoculation densities used in CCA cell lines throughout cytotoxicity
testing in 96 well plates are shown in Table 6.
Cell Line Inoculation density (per well)
HUCC-T1 20,000
SkChA-1 20,000
M213 10,000
Table 6 Inoculation densities used in CCA cell lines
3.3.2 Cytotoxicity assays
3.3.2.1 Preliminary experiments
To ensure experimental validity, a series of quality control experiments were carried
out to optimise the methodology.
Cell lines were exposed to DMSO in the absence of cytotoxic agents to ensure that
this solvent was not contributing to cell death at the concentrations used. Although
previously shown not to affect cell studies at the concentrations used in these
experiments, DMSO has not been tested with the particular cell lines used in these
experiments (see section 3.2.6.1.5).
The method of adding chemotherapy agents to growing cells varied from reviewing
published protocols (Houghton et al., 2007, Vichai and Kirtikara, 2006). Once cells
were added to a 96 well plate suspended in 100µL of culture medium, they were
allowed 24 hours to adhere before addition of the agent under scrutiny. One option
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was to remove the original medium and replacing it with 200µL of fresh medium
containing the agent at the appropriate concentration. The other option was to
leave the 100µL of medium in the 96WP and just add another 100µL of agent
suspended in medium at double the intended final concentration. Preliminary
experiments were performed to check whether there would be a difference in these
two methods.
3.3.2.1.1 Exposure to DMSO
The graphs below illustrate the effect of DMSO on CCA cell lines. Increasing
concentration of DMSO has not altered cell culture growth pattern.
Figure 3-10 DMSO effect on SkChA1
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Figure 3-11 DMSO effect on HUCC
3.3.2.1.2 Removal vs non removal of medium prior to addition of cytotoxic agent
The graphs below represent a series of experiments to check the effect of removal of
medium prior to the addition of cytotoxic agent as compared to addition of further
medium with double concentration of the cytotoxic agent.
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Figure 3-12 SkChA1 cell line exposed to Gemcitabine (comparison between two methodologies)
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Figure 3-13 HUCC cell line exposed to Gemcitabine (comparison between two methodologies)
Complete renewal increases the amount of culture medium available and removes
waste products of metabolism. On the other hand by removing the medium from the
96WP, there is a risk of aspirating adherent cells, and this could be done
disproportionately between wells. The extra step also adds extra risk of
contamination, either by introducing an infection or by cross contaminating wells
with the wrong cells. Finally there is a risk of dilution discrepancies, as aspirating
100% of the 100µL is technically challenging. There was no significant difference
observed between the two methodologies above. As such the method of ‘no
medium change’ was used thereafter in all cytotoxic experiments.
3.3.2.2 Single agent testing
3.3.2.2.1 Cisplatin
The dose response curves of the selected cell lines to cisplatin monotherapy are
shown below.
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Figure 3-14 Cisplatin effect on HUCC Cells
Cisplatin effect on SkChA1 cells
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Figure 3-15 Cisplatin effect on SkChA1 cells
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Figure 3-16 Cisplatin effect on KKU M213 cells
3.3.2.2.2 Cisplatin in combination with PK11195
The dose response curves of cell lines exposed to cisplatin monotherapy in the
presence or absence of PK11195 are shown below. Visual inspection of the graphs
shows that PK11195 enhanced the effect of cisplatin in all cell lines at varying
degrees. However, when examined using 2 way ANOVA, this enhancement was not
always statistically significant. If statistically significant, the greatest percentage
enhancement is given in the text following each graph along with the concentration
of cytotoxic agent at which this occurred.
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Figure 3-17 Effect of PK11195 addition to cisplatin on KKU M213 cells
The addition of PK11195 to cisplatin therapy in KKU M213 cells resulted in a
significant enhancement of cytotoxic effect. The largest effect was seen at a
concentration of 1x10-6 mM as indicated by the graph above (Figure 3-17). At this
concentration PK11195 enhanced the action of cisplatin by 73.10% (95% CI: 49.44-
96.83%, P<0.001).
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Figure 3-18 Effect of PK11195 addition to cisplatin on SkChA1 cells
The addition of PK11195 to cisplatin therapy in SkChA1 cells did not have a
significant effect in any concentration. The only concentration that it had a minimal
effect was at 1x10-8 M, an enhancement of 20%, but this was not statistically
significant (P>0.05).
Cell line cytotoxicity assays
88
-10 -8 -6 -4 -2
0.0
0.5
1.0
1.5
2.0
Cisplatin
PK11195
Combination
Cisplatin Concentration
Fr
ac
tio
n 
of
 O
D
Figure 3-19 Effect of PK11195 addition to cisplatin on HUCC cells
The addition of PK11195 to cisplatin therapy in HUCC cells did not have a significant
effect in any concentration. The only concentration that it had a minimal effect was
at 1x10-9 M, an enhancement of 0.2%, which was not statistically significant (P>0.05).
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3.3.2.2.3 Gemcitabine
The dose response curves of the cell lines to gemcitabine monotherapy are displayed
below.
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Figure 3-20 Gemcitabine effect on SkChA1 cells
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Figure 3-21 Gemcitabine effect on HUCC cells
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Figure 3-22 Gemcitabine effect on KKU M213 cells
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3.3.2.2.4 Gemcitabine in combination with PK11195
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Figure 3-23 Effect of PK11195 addition to gemcitabine on SkChA1 cells
The addition of PK11195 to gemcitabine in SkChA1 cells resulted in a significant
enhancement of cytotoxic effect. The largest effect was seen at a concentration of
1x10-8 mM as indicated by the graph above (Figure 3-23). At this concentration
PK11195 enhanced the action of gemcitabine by a mean of 30.24% (95% CI: 4.67% to
55.78%, P<0.001).
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Figure 3-24 Effect of PK11195 addition to gemcitabine on HUCC cells
The addition of PK11195 to gemcitabine in HUCC cells resulted in a significant
enhancement of cytotoxic effect. The largest effect was seen at a concentration of
1x10-9 mM as indicated by the graph above (Figure 3-24). At this concentration
PK11195 enhanced the action of gemcitabine by a mean of 23.31% (95% CI: 40.91%
to 5.80%, P<0.001).
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Figure 3-25 Effect of PK11195 addition to gemcitabine on KKU M213 cells
The addition of PK11195 to gemcitabine in KKU M213 cells resulted in a significant
enhancement of cytotoxic effect. The largest effect was seen at a concentration of
1x10-9 mM as indicated by the graph above (Figure 3-25Figure 3-24). At this
concentration PK11195 enhanced the action of gemcitabine by a mean of 14.07%
(95% CI: 5.83% to 22.87%, P<0.001).
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3.3.2.2.5 Fluorouracil
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Figure 3-26 Fluorouracil effect on SkChA1 cells
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Figure 3-27 Fluorouracil effect on HUCC cells
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Figure 3-28 Fluorouracil effect on KKU M213 cells
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3.3.2.2.6 Fluorouracil in combination with PK11195
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Figure 3-29 Effect of PK11195 addition to 5FU on HUCC cell line
The addition of PK11195 to 5FU therapy in HUCC cells did not have a significant
effect in any concentration. An effect was observed at 1x10-6 M, an enhancement of
23.38% (95% CI: 6.76 to 53.54%) which was, however, not statistically significant
(P>0.05).
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Figure 3-30 Effect of PK11195 addition to 5FU on KKU M213 cell line
The addition of PK11195 to 5FU in KKUM213 cells resulted in a significant
enhancement of cytotoxic effect. The largest effect was seen at a concentration of
1x10-7 mM as indicated by the graph above (Figure 3-30). At this concentration
PK11195 enhanced the action of 5FU by a mean of 24.99% (95% CI: 3.02% to 46.89%,
P<0.01).
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Figure 3-31 Effect of PK11195 addition to 5FU on SkChA1 cell line
The addition of PK11195 to 5FU in SkChA1 cells resulted in a significant
enhancement of cytotoxic effect. The largest effect was seen at a concentration of
1x10-8 mM as indicated by the graph above (Figure 3-31). At this concentration
PK11195 enhanced the action of 5FU by a mean of 33.81% (95% CI: 7.93% to 59.71%,
P<0.001).
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3.3.2.2.7 Etoposide
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Figure 3-32 Etoposide effect on SkChA1 cells
The IC50 was 2.42x10-5 M.
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Figure 3-33 Etoposide effect on HUCC cells
The IC50 was 2.317x10-5 M.
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Figure 3-34 Etoposide effect on KKU M213 cells
The IC50 was 3.422x10-7M.
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3.3.2.2.8 Etoposide in combination with PK11195.
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Figure 3-35 Effect of PK11195 addition to Etoposide on SkChA1 cell line
The addition of PK11195 to etoposide therapy in SkChA1 cells did not have a
significant effect at any concentration. The largest effect was observed at 1x10-7mM,
an average enhancement of 15.9%, which was not statistically significant (P>0.05).
Comparing the dose response curve as a whole, the IC50 was reduced from
1.986x10-6 mM (etoposide monotherapy) to 1.372x10-6 mM (combination
PK11195/etoposide), representing a 31% reduction.
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Figure 3-36 Effect of PK11195 addition to Etoposide on HUCC cell line
The addition of PK11195 to etoposide therapy in HUCC cells did not have a
significant effect at any concentration. A small effect was observed at 1x10-5mM, an
average enhancement of 3.98%, which was not statistically significant (P>0.05).
Comparing the dose response curve as a whole, the IC50 was reduced from 1.34x10-6
mM (etoposide monotherapy) to 1.11x10-6 mM (combination PK11195/etoposide),
representing a 16.9% reduction.
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Figure 3-37 Effect of PK11195 addition to Etoposide on KKU M213 cell line
The addition of PK11195 to etoposide in KKU M213 cells resulted in a significant
enhancement of cytotoxic effect. The largest effect was seen at a concentration of
1x10-9 as indicated by the graph above (Figure 3-37). At this concentration PK11195
enhanced the action of 5FU by a mean of 34.54% (95% CI: 4.03% to 65.05%, P<0.01).
Comparing the dose response curve as a whole, the IC50 was reduced from 8.39x10-8
mM (etoposide monotherapy) to 5.83x10-8 mM (combination PK11195/etoposide),
representing a 30.47% reduction.
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Cell line Most effectiveagent
Concentration
(mM)
% enhancement by
PK11195 (95% CI)
P -
value
SkChA-1 Fluorouracil 1x10 8 33.81%(7.93-59.71%) P<0.001
HuCC T-1 Gemcitabine 1x10- 9 23.31%(5.80-40.91%) P<0.001
KKU M213 Cisplatin 1x10-6 73.10%(49.44-96.83%) P<0.001
Table 7 Greatest effect achieved with PK11195 for each cell line
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3.3.2.3 Cytotoxic agent combination
In this series of experiments all agents were combined in all possible permutations
with each other to determine the most effective combination therapy for each
particular cell line. The most effective combination (for each cell line) was then re
tested in the presence or absence of PK11195 to determine if there was any
additional benefit.
3.3.2.3.1 SkChA1 cell line
The most potent combination regime to treat the SkChA1 cell line (when compared
to the single agents independently) was gemcitabine and etoposide.  This
combination regime was most effective at a drug concentration of 1x10-9mM, the
most dilute of concentrations tested. Compared to etoposide alone, the combination
was 46.57% more effective.
Subsequent addition of PK11195 to the above regime, however, had little effect (see
Figure 3-38). In fact at a concentration of 1x10-8 mM, PK11195 had statistically
significant inhibitory effect of -24.75% on the drug regime (i.e. the addition of
PK11195 resulted in a less potent action) (P<0.01).
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Figure 3-38 Addition of PK11195 to Etoposide and Gemcitabine combination in SkChA1 cells
3.3.2.3.2 HUCC Cell line
In this cell line, the most potent combination was gemcitabine with cisplatin.
Addition of PK11195 again did not have the desired effect, reducing the
combination’s effect at the lowest concentration (1x10-9mM), by -18.34% (P<0.01)
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Figure 3-39 Addition of PK11195 to gemcitabine and cisplatin combination in HUCC cells
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3.3.2.3.3 KKU M213 cell line
In this cell line, the most potent drug combination was etoposide with 5FU. Addition
of PK11195 to the combination therapy had no statistically significant effect at any
concentration. In addition, unlike the other two cell lines, there was no reduction in
potency by adding PK11195 at any concentration.
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Figure 3-40 Addition of PK11195 to etoposide and 5FU combination in KKU M213 cells
3.3.3 Qrt-PCR results
Each sample was analysed in technical duplicate. All samples were normalised to the
endogenous control gene, β-actin. There was no inter analysis variation between the
two technical replicates of each sample indicating that there was no evidence of
contamination or pipetting error in these experiments.
Figure 3-41 shows the amplification curves, plotting the cycle number against
fluorescence (Rn – arbitrary reading) for all the cell lines used. The cell line H69 was
also included although not part of the cytotoxic and PK11195 experiments. The ΔCt
value represents the point at which the sigmoid curve starts to exponentially
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amplify.  The sigmoid curves which are lying more to the left indicate that Bcl-2
levels are detected at an earlier PCR cycle, in turn indicating higher levels of
expression.  From the plot in Figure 3-41 we can see that HUCC has the highest levels
of Bcl-2 expression followed by SkChA1, with M213 having the lowest levels.
Figure 3-41 Bcl-2 amplification curves
Figure 3-42 represents the relative abundance of Bcl-2 (in arbitrary units) for the
three cell lines used in the PK11195 experiments. The lower the ΔCt values in Figure
3-41, the higher the expression of Bcl-2. There was no co-relation between the level
of Bcl-2 expression and the response to PK11195 enhancement.
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Figure 3-42 Level of Bcl-2 expression (arbitrary values)
3.4 Discussion
Analysis of the action of individual cytotoxics (monotherapy) on all cell lines
demonstrated that, to varying degrees, all had an inhibitory effect on cell growth.
The growth inhibition curves, however, were quite heterogeneous and consequently
the IC50 for each cell line also varied.
There could be various explanations for these results, however, two are the most
obvious: Firstly, the assumption has been made that the cell lines used represent the
original diseases they were harvested from. This is not necessarily true as in cell
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culture, daughter cells deviate both in genetic terms and property terms from parent
cells, more so as the passage number increases (Wenger et al., 2004). As an
indication the cell line SkChA1 was at passage number 50 and HUCC was at passage
number 90 at time of use in these experiments. Even if the primary cell cultures of
these lines, and by extrapolation the original disease, had been sensitive to the same
cytotoxic agents, the actual cells used could have developed resistance to distinct
cytotoxic agents.
Secondly, it has been repeatedly suggested that EH (represented by cell line SkChA1)
and IH CCA (represented by HUCC) may in fact represent different, distinct diseases.
Although traditionally in receipt of a common approach, several groups have
suggested a rethink to the above and for tailoring management separately to these
subcategories (Braconi and Patel, 2010). Furthermore, the IH CCA originating from
South East Asia (represented by cell line KKU M213) may also represent a third,
distinct entity (Suzuki et al., 2000). Consequently these potentially 3 different
diseases might well respond to three distinct chemotherapy regimens.
Application of two drugs to a system can result in the same response as the sum of
the two drugs individually (additive), a greater response (synergistic) or a lesser
response (antagonistic, where one drug blocks the effects of the other). Studies in
the combined action of biologically active agents, most notably cytotoxic and
antimicrobial drugs have generated much debate, particularly in search of
potentially potent drug regimens at a preclinical stage. However, there is little
consensus over terminology, definitions and models for the evaluation of these
interactions (Greco et al., 1996). As such, there has been no standardisation of
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methodology despite several (at least 16) published approaches for assessing
combined action data (Greco et al., 1995). Some of the described approaches use
specialised software and complex data simulation to create 3D graphical
representations using response surface methodology (Dressler et al., 1999).
A simple approach for assessing drug interaction was adopted in these experiments,
by comparing the IC50 of each agent separately and then in combination. The
rationale for this was in order to determine the most active combination for each
cell line, and then subsequently to see how this combined activity could be
enhanced by the addition of PK11195.
Testing of combination therapies revealed similar results to those observed in
monotherapy: that different cell lines responded differently to separate regimes. If
these results are correlated to clinical trials then one would expect that CCA cell lines
would respond best to the regimes currently used in human cancer patients. The
standard of care for all CCA patients is currently a combination of gemcitabine and
cisplatin (Valle et al., 2010b). Although all cell lines responded (to varying degrees) to
this regime, this regime represented the most potent combination only for the HUCC
cell line (derived from an IH CCA in a Japanese patient). The patient characteristics of
the subjects enrolled in this study included a sizable group of IH CCA, however, this
was a multicentre UK-based study, and likely to represent a local population.
Arguably the cell line closest to this patient makeup is SkChA1, derived from an EH
CCA patient from Germany. However, this cell line responded best to the
combination of gemcitabine with etoposide, a regime that is currently at phase II
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trials in other cancers, but not tested in CCA to date (Bruzzone et al., 2011, Melnik et
al., 2010).
The addition of PK11195 to cytotoxic agents produced some interesting results. Of
particular note was that on its own, PK11195 had a consistent effect on all cell lines:
unless it was administered at a very high concentration (> 1x10-4mM), it had little to
no effect on cell growth. At very high concentrations, however, it had a marked
inhibitory effect on all cell lines.
When PK11195 was added to cytotoxic monotherapy, more often than not it
enhanced the effect of that particular cytotoxic agent. The magnitude of this effect
again varied according to the cell line and cytotoxic agent used. The explanation for
this could be argued along the same lines as above, in the second paragraph of the
discussion section.
Time and budget constraints did not allow for testing of PK11195 on all the possible
chemotherapy combinations in all the cell lines. Hence, it was only tested against the
most potent combination for each particular cell line. Addition of PK11195 to these
regimens though did not have the same effect as for monotherapy testing. It failed
to enhance the effect of any of the tested regimes, in some cases causing an
apparent inhibitory effect, although in most cases this was not statistically
significant.
The levels of Bcl-2 expression were investigated in an attempt to explain the
differences in response to PK11195, especially as illustrated by its additional effect
on monotherapy regimens. Bcl-2 is an anti-apoptotic protein, higher levels of which
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result in cell survival advantage. It is well documented that cancer cells can express
higher levels of Bcl-2 thus evading apoptosis (Placzek et al., 2010). High levels of Bcl-
2 in some cancers have been described as a marker of poor prognosis. For example
in prostate cancer, Bcl-2 detection was much more common in androgen
independent samples (McDonnell et al., 1992). This observation has led to targeting
apoptosis suppressors as a route of developing cancer therapeutics.
PK11195 is a peripheral benzodiazepine receptor inhibitor. It acts by inhibiting Bcl-2
and therefore rebalancing the equilibrium and restoring the sensitivity of cancer cells
to pro-apoptotic signals. Therefore, in theory at least, cells expressing higher levels
of Bcl-2 (expressed as Bcl-2 mRNA) should have an enhanced response to
chemotherapy when exposed simultaneously to PK11195. Simply put, cell damage
from cytotoxic agents would channel them into apoptosis, and PK1195 would allow
that process to occur.
These experiments did not demonstrate this. Although all cell lines responded better
to chemotherapy in the presence of PK11195, the maximum difference was
observed in the cell line KKU M213, where PK11195 enhanced the action of cisplatin
by 73.1% (at a concentration of 1x10-6 mM, see Figure 3-17). Cell line KKU M213,
however, expressed the lowest level of Bcl-2 of all three cell lines used (see Figure
3-42). On the other hand, cell line HUCC which showed the highest levels of Bcl-2
expression had the smallest enhancement when PK11195 was added to gemcitabine.
Whether Bcl-2 plays a significant role in cholangiocarcinogenesis is not clear from
the current literature. One study reported 8 out of 11 human CCA samples
demonstrating Bcl-2 on immunohistochemistry with the authors going as far as
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suggesting Bcl-2 could represent a distinguishing feature from hepatocellular
carcinoma (Charlotte et al., 1994). However, this observation has not been
consistent with other studies finding little or no expression of Bcl-2 in CCA (Okaro et
al., 2001).
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4 The proteomic analysis of cholangiocarcinoma cell lines
4.1 Introduction to Proteomics
Proteomics is the study of the entire protein complement of an organism. As a
science it has exponentially expanded over the last two decades, principally driven
by improvements in the annotation of the human genome and technical
developments in mass spectrometry. The human genome contains 20-25,000 genes
which encode over 100,000 different proteins (Orchard et al., 2005, Keren et al.,
2010). The transcripts that link the genome to the proteome have variable
degradation rates and translation efficiencies and are subjected to different
processes that differentially alter translation, such as alternative splicing, micro RNA-
induced terminations and translation in different reading frames. The resultant
proteins are then subject to post-translational modifications that also impact on
their function such as phosphorylation and glycosylation. This increasing level of
complexity from the genome through the transcriptome to the proteome renders
the assumption that accurate protein expression can be determined by studying
genes or transcripts questionable. Indeed, a review of the published literature
suggests that the link between gene and protein expression is perhaps better
described as a trend than a correlation (Maier et al., 2009). Therefore, as the only
discipline which studies the functional end-product of gene expression, proteomics
could be viewed as the “gold standard” method by which to identify candidate
biomarkers, vaccines or therapeutic targets.
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Prior to the development of mass spectrometry-based proteomics, researchers
studying protein expression were restricted to antibody-dependent techniques:
either by Western Blotting (where a crude protein mixture is separated by gel
electrophoresis, transferred to a membrane and then probed with an antibody) or by
immunohistochemistry. Although both techniques are still very relevant and widely
used today, they are dependent on the availability of antibodies and therefore can
only be used where questions relating to the expression of previously known
proteins for which antibodies are available are being addressed. The advantage of a
mass spectrometry-based study is that protein expression levels can be compared
between groups using crude protein mixtures without any preconceptions. Then,
identities can be retrospectively assigned to those proteins that are found to be
differentially expressed without any hypotheses as to what their identities might be.
4.1.1 Mass spectrometry and identification of proteins
A mass spectrometer extremely accurately (often with sub part per million accuracy)
measures the molecular mass of either intact proteins, or more usually its peptides.
Peptides rather than proteins are generally used in proteomics because they are
smaller (and are therefore more easily vaporised) and because they yield more data;
analysing a protein by mass spectrometry determines its mass but analysing its
peptides yields its amino acid sequence. Although there is a confusing array of
different types of mass spectrometers named with various acronyms, their
fundamental method of working can be broken down into three parts; a means of
vaporizing and ionising the peptides, a means of separating the peptides by their
mass and a means of detecting them. There are two common ionisation methods
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(“electrospray ionisation” and “matrix-assisted laser desorbtion/ionisation (MALDI))
and several means of separation in different kinds of “mass analyser” (including
“time of flight” (ToF)).  The work in this project was carried out on a MALDI-ToF/ToF
mass spectrometer and a brief description of how it works follows.
In MALDI, the protein to be identified is digested into peptides using trypsin. The
peptides are then co-crystallized as a spot on a stainless steel plate with “matrix”
(commonly α-cyano-4-hydroxycinnami acid). The plate is inserted into the mass
spectrometer and a laser directed at the spot. Photons from the laser are adsorbed
by the aromatic rings of the matrix and transferred to the peptides along with a
proton, causing the now-positively charged peptides to vaporise. A strong negative
electromagnetic field propels the peptide ions into the mass analyser, which consists
of a vacuumated flight tube ending in a detector. The trajectory time of a peptide
through the flight tube is dependent on its mass-to-charge-ratio (m/z), so the
different peptide ions separate in flight and are detected sequentially as they impact
the detector. Thus, each protein is recorded as a mass spectrum with m/z on the x-
axis and ion intensity on the y-axis. Each peak on the mass spectrum represents one
of the peptides derived from the intact protein, its m/z being dependent on its
amino acid sequence. As α-cyano-4-hydroxycinnamic acid only protonates each
peptide singly, the charge of each ion is 1+ so the mass of each peptide can be easily
calculated from the m/z. This spectrum of ions is unique to each protein and is called
a “peptide mass fingerprint” (PMF). In the past, PMFs were routinely used to assign
identities to proteins (Pappin et al., 1993). This was done by a computer program
loaded with a database of protein sequences. The computer would carry out a
The proteomic analysis of cholangiocarcinoma cell lines
118
theoretical in silico, tryptic digest of each protein in the database and then calculate
the molecular mass of each peptide by summing the masses of the peptide’s
component amino acids. Then, by matching the PMF’s experimental masses
obtained by the mass spectrometer to the theoretical masses derived by the
computer an identity could be obtained. However, over the last decade more
sophisticated mass spectrometers have become commonly available which fragment
the peptides in a second round of mass spectrometry so their amino acid sequences
can also be determined. Also, protein database sizes have increased exponentially
such that PMF-derived identities are unreliable because of the consequent high
numbers of false-positive protein identities.
The process in which two rounds of mass spectrometry are undertaken and the
“precursor” or “mother” PMF ions are fragmented into their “daughter ions” is
called “tandem mass spectrometry”. When the mass spectrometer is fitted with a
MALDI ion source connected to a time of flight mass analyser the process is called
MALDI-ToF/ToF mass spectrometry (or MALDI-MSMS). In the second round of MS,
peptide ions are ionised from the MALDI plate a second time using the laser and are
fired into the mass spectrometer using their electromagnetic charge. This time
however, a timed ion selector and a collision cell filled with nitrogen are placed in
the trajectory path of the ions. The timed ion selector uses electronic gates to isolate
a precursor ion that has been pre-selected from the PMF, usually chosen on account
of its high ion intensity (i.e. it is very amenable to ionisation) and size (it needs to
contain sufficient numbers of amino acids to yield a potentially diagnostic sequence).
The precursor ion then enters the collision cell and fragments on impact with the
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nitrogen. Each daughter ion traverses the flight tube, impacts the detector and forms
part of what is called the “MSMS spectrum”. After one mother ion has been
fragmented into daughter ions and the MSMS spectrum obtained, the process can
be repeated for other mother ions chosen from the PMF. Once the set of MSMS
spectra have been obtained from the PMF each is converted into its amino acid
sequence (Johnson et al., 1987). These amino acid sequences can then be matched
against those from a protein database and the identity of the previously unknown
protein established. As each protein identity is obtained using the amino acid
sequence of several peptides, rather than from the PMF (just masses of peptides) a
protein identity can be assigned with extremely high confidence.
4.1.2 Study design in proteomics
There are two commonly used but fundamentally different ways that samples are
compared in a proteomic experiment: “shotgun proteomics” and two-dimensional
gel-based proteomics.
In shotgun proteomics a crude protein mixture is digested into peptides. The
peptides are then separated on a high performance liquid chromatography (HPLC)
system that is coupled to a mass spectrometer. The peptides are eluted off the HPLC
column and are vaporized by electrospray ionisation as they enter the mass
spectrometer in solution. Between-sample expression levels are determined, either
by differential labelling of the peptides from each sample or by label-free
quantification. Label-free quantification works on the premise that the intensity of
the peptide signal detected by the mass spectrometer is proportional to the
expression level of the intact protein (Elliott et al., 2009). Although shotgun
The proteomic analysis of cholangiocarcinoma cell lines
120
proteomics has many strengths, fundamental disadvantages are that large amounts
of mass spectrometry time are required, subtly different protein isoforms and are
difficult to distinguish from each other and a lot of data is lost because the mass
spectrometer’s cycling speed is too slow to keep up with the pace at which peptides
are delivered by the HPLC system. Long HPLC gradients help to separate and elute
the tens of thousands of peptides at a speed slow enough for the mass spectrometer
to process them, but ultimately it is necessary to separate the peptides in more than
one dimension, if more than approximately 500 proteins are to be analysed. Also,
multiple biological and technical replicates are required because peptides are not
inherently quantitative (they exhibit a range of variable physiological properties
(such as charge and hydrophobicity) which lead to large differences in mass
spectrometric response (Bantscheff et al., 2007)). Thus, the technique is extremely
expensive for research groups who rent time on instruments in a specialist facility.
Whether labelled or label-free quantification is chosen, all of the peptides need to be
assigned to their parent proteins by a second round of MSMS analysis where each
mother peptide is fragmented into its daughter peptides to obtain its amino acid
sequence. As all of the peptides from all of the proteins are mixed together at the
start of the process, it is difficult to quantify proteins that have a high degree of
homology at the amino acid level, because a large proportion of their peptides will
be identical, become eluted from the HPLC column at the same time and are
therefore indistinguishable.
The principal alternative to shotgun proteomics is two-dimensional gel-based
proteomics, where, unlike shotgun proteomics, the proteins are separated and
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analysed whilst they are still intact. The crude protein mixture is prepared in a non-
ionic buffer and absorbed into a strip that incorporates a pH gradient. When an
electrical current is passed through the strip the proteins undergo isoelectric
focussing (IEF) and migrate to the point at which they have no net charge (their
isoelectric point (pI)). The entire strip is then soaked in SDS (which renders all of the
proteins negatively charged) and then placed at the top of a polyacrylamide gel. A
current is then passed through the gel and the proteins (already separated by charge
in the first dimension) now separate in the gel by molecular mass. The result is a gel
containing numerous spots, each spot representing a different protein, the
coordinates of which are determined by its charge and mass. Multiple IEF strips and
gels can be run at once, each one containing a different sample, so when the spot
patterns from the different gels are compared differential protein expression
between the samples can be seen. Those differentially-expressed spots are then
physically cut from the gel, digested by trypsin and identities assigned to them using
MALDI-ToF/ToF mass spectrometry.
As identities are only sought for the differentially-expressed spots, the process takes
minimal mass spectrometry time compared with a shotgun proteomics experiment
and is therefore considerably less costly. Also, as the protein expression analysis is
carried out at the protein level rather than at the peptide level, extremely similar
proteins can still be visualised as separate entities. The problem of matching peptide
intensity levels to protein expression levels is also avoided. The principal
disadvantage of the gel-based method is that a significant proportion of the
proteome is excluded from the analysis. These include highly hydrophobic
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membrane proteins (that cannot be solubilized in the non-ionic buffer), proteins of
extreme charge (whose pI falls outside the range of the IEF strip) or proteins of
extreme molecular mass (that are either too large to enter the gel or are so small
that the gel cannot resolve them). Some users cite technical difficulties, the time-
consuming nature and inherent gel-to-gel variation as problems. The latter issue has
been resolved by the development of two-dimensional difference gel
electrophoresis (2D-DIGE) (Tonge et al., 2001). In 2D-DIGE, gel-to-gel variation is
eliminated by multiplexing the samples: each gel contains a pooled internal standard
(labelled with a fluorescent CyDye) that is made up from all of the samples in the
experiment (so it contains all of the spots in all the gels) as well as the sample under
scrutiny (labelled with a different CyDye). As the internal standard is identical in all
the gels, it is easy to match the gels in the experiment to each other. The expression
level of each spot is then assessed as a proportion of its equivalent internal standard
spot in the same gel. These proportions are then compared between the gels and
this way gel-to-gel variation is eliminated and highly reproducible results are
obtained (Karp et al., 2005, Jackson et al., 2009).
4.1.3 Proteomics and cancer research
The clinical application of proteomics in cancer research is seen as most promising in
three distinct areas: the identification of biomarkers to aid in the diagnosis and
prognosis and the detection of unique targets that could potentially guide drug
development. A large proportion of clinical proteomic work has focused specifically
on cancer diagnosis and therapy and there has been an exponential increase in the
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number of publications in this area. As expected, most of the research carried out
has focused on cancers that have a higher incidence and prevalence.
Biomarker discovery has long been considered a rational approach for the
development of diagnostic tests in cancer. Clinically useful cancer biomarkers would
provide earlier and better diagnosis of patients (enabling intervention at the early
stages of the disease where the chance of it being effective is greatest) and
prognostic biomarkers would enable patients to be better monitored during the
course of treatment (Schilsky, 2010).
Despite the plethora of work in this area, no reliable protein biomarkers have been
developed that return sufficiently high sensitivity and specificity values. The problem
is well-illustrated when considering the epithelial ovarian cancer biomarker CA125.
CA125 is potentially expressed in 50-90% of patients with ovarian cancer, depending
on the stage, histologic subtype and the study (Moss et al., 2005, Kobel et al., 2008).
Although its expression corresponds well with initial therapy, the poor sensitivity of
CA125 leads to anxiety and deterioration in the quality of life in asymptomatic
patients, such that withholding treatment in the event of isolated rising CA125 levels
will not negatively impact overall survival (Rustin et al., 2009).
4.1.4 Proteomics and cholangiocarcinoma
There is a particular need to identify new proteomic targets that can be used as
either biomarkers or chemotherapeutic targets in CCA as currently neither
chemotherapy nor radiotherapy radically effects patient survival. Furthermore, as
early detection with surgical intervention offers the best chance of survival, it follows
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that a biomarker capable of detecting disease at the earliest possible stage would
also improve survival and outcomes.
The current biomarkers associated with the detection of biliary tree cancers are CEA
and Ca 19-9. Their sensitivities however are reported as approximately 70% and 50%
respectively, (Scarlett et al., 2006). Specificity of these biomarkers is similarly low.
Ca19-9 can be also elevated in pancreatic cancer, gastric cancer, and primary biliary
cirrhosis, and is also elevated in smokers.
Ca 19-9 and CEA also seem to have some value as a prognostic marker as expression
corresponds well with response to initial therapy.High levels, especially of Ca19-9
appear to be a poor prognostic indicator (Briggs et al., 2009). Overall, it is safe to say
there is a pressing need for more reliable markers for CCA.
Despite this evident need, there has been little work describing meaningful quantitative proteomic
analyses of CCA. Indicative is a simple database search for the strings [(proteomics OR proteome)
AND cholangiocarcinoma]. This search returns a total of 31 studies without any date or study type
restrictions. Table 8 Number of proteomic related articles published in PubMed for various cancers
shows the extent to which other cancers have been investigated when applying the
equivalent search strings.
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Cancer Number of articles
Breast cancer 1077
Lung cancer 621
Colorectal cancer 593
Prostate cancer 535
Hepatocellular cancer 460
Pancreatic cancer 320
Table 8 Number of proteomic related articles published in PubMed for various cancers
The first study compared the CCA membrane proteome with that from normal biliary
tissue (Kristiansen et al., 2008). The samples were selectively enriched for membrane
proteins then analysed using a technique similar to shotgun proteomics in that
protein quantification was carried out at the peptide level. A total of 52 proteins
were found to be up regulated in the CCA samples, including proteins known to be
associated with CCA (such as mucins and CEA) and some novel proteins. However,
the sample size was small, consisting of only two CCA samples and one normal
sample, the former of which were human xenografts grown in athymic mice.
Therefore, it is unclear how much of the proteomic differences observed by
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Kristiansen et al were due to the small sample size or the comparison of a xenograft
grown in an immunologically depleted mouse and a human clinical specimen.
The xenograft study was followed by one where paired tumour and normal tissue,
taken at the time of radical surgery from two patients with CCA, were analysed by
shotgun proteomics (Kawase et al., 2009). A total of 38 proteins were found to be up
regulated in the CCA samples, 4 of which were verified by Western Blotting on four
further matched CCA and normal biosamples. Although the verified proteins (actinin
1 and 4, protein DJ-1 and cathepsin B) have previously been associated with other
cancers, none of them were amongst the potential biomarkers previously
highlighted in the Kristiansen et al xenograft paper. This is possibly because, again,
the sample sizes were too small and/or that the CCA was occupying only a
proportion of the tissue in the “tumour” samples, with much of the remaining
biosample consisting of stromal tissue, rich in inflammatory cells and fibroblasts.
The stromal heterogeneity “contamination” issue was addressed by a study in which
intrahepatic CCA tissue was selectively extracted for analysis using laser capture
micro dissection (Dos Santos et al., 2010). In this study, the inherent difficulty of
sample paucity associated with laser capture micro dissection was overcome using a
specialist technique called “accurate mass and time tagging” where Fourier
transform ion cyclone resonance mass spectrometry is coupled to a nano HPLC
system enabling minute sample quantities to be analysed (Shen et al., 2004). Dos
Santos et al collected intrahepatic CCA samples at the time of surgical resection from
four patients, isolated the CCA cells and compared their proteome with
cholangiocytes from five non-cancerous controls. The proteomic data was obtained
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in a shotgun proteomics approach, and the identities of interest verified using a
Tissue Microarray made from 59 CCA samples and 22 normal controls. A total of 460
proteins were identified with an acceptable degree of confidence, but it is notable
that there was significantly more proteomic between-patient heterogeneity in the
specifically-selected intrahepatic CCA cells than in the cholangiocyte controls. This
result demonstrates the absolute requirement for sample sizes to be larger than
those of the work published to date if anything other than superficial data is to be
obtained. When the CCA samples were compared with the controls, Don Santos et al
found 39 of the 460 proteins to be differentially expressed, three of which (vimentin
and carbonic anhydrase II) were verified using the tissue microarray. Neither of
these proteins had been identified in the earlier Kawase et al (2009) paper, but they
are both identified as being differentially expressed in Kristiansen et al (2008).
However, vimentin was downregulated in the Kristiansen paper and up regulated in
the Don Santos study and the opposite was the case for carbonic anhydrase II. Thus,
it is impossible to draw meaningful conclusions from these two studies.
The most recent study analysed snap frozen samples from 4 patients with
intrahepatic CCA (Darby et al., 2010). This study performed 2D DIGE using an internal
standard prepared with equal volumes of the CCA and control samples, thus
eliminating technical error. The experiment used large 24cm gels each of which
contained a differentially labelled CCA, liver tissue and internal standard sample. The
major shortfalls of this study were its small patient sample and the use of normal
liver tissue as a control. It is unclear how much of the differences observed represent
a comparison of biliary vs. liver tissue as opposed to tumour vs. normal tissue. A
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total of 138 different proteins were identified by mass spectrometry to have
different expression levels, of which 70 were over expressed and 68 under expressed
in the tumoural samples. The authors concentrated their discussion on the roles of
protein 14-3-3, periostin and alpha smooth muscle actin.
Rather than interrogate tissue samples, an alternative avenue of research is to
analyse bile. Bile should theoretically be enriched in CCA-derived proteins and is
obtainable using endoscopic retrograde cholangiopancreatography so is potentially
useful in diagnosis. In the first proteomic analysis of bile, 87 proteins were identified
from a sample taken a CCA patient, including carbonic anhydrase and mucin 2
(Kristiansen et al., 2004). This has been followed by a recent study in which bile from
4 CCA patients was analysed (Farid et al., 2011), with nearly 500 proteins being
identified in each patient with confidence (i.e. with at least two significant peptides),
including mucin 1 and vimentin. However, there was only a relatively small degree of
overlap in the list of proteins present, such that only 185 proteins were present in all
four patients. Thus, it appears likely that bile, as is the case with serum, will prove to
be a highly variable medium in which it will be difficult to search for biomarkers.
However, the practical difficulties in purifying the relatively low protein content of
bile and removing the bile salts, bile acids and lipids that could prejudice proteomic
research have clearly been resolved. Indeed, a protocol has recently been published
in which over 2500 proteins were identified in the bile of calculus (gallstone)
cholecystitis patients (Barbhuiya et al., 2011).
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4.1.5 Proteomic analysis of CCA cell lines
The use of cell lines in cancer proteomic research confers advantages and
disadvantages along similar lines to those discussed earlier in cytotoxic drug
evaluation (see section 1.2.1). Advantages such as low cost, unlimited supply and
sample purity make them very attractive for initial evaluation. However, the in vitro
expression of proteins and differences from the original tumour tissue several after
subculture are limitations that must be taken into account when interpreting the
results.
The first proteomic study of a CCA cell line was a 2D gel study where the Thai CCA
HuCC-A1 cell line was compared to two hepatocellular carcinoma cell lines
(Srisomsap et al., 2004). Differential expression of cytokeratins and vimentin were
found. This was followed by a more in-depth study where the crude protein mixture
from the same cell lines were separated into two fractions using different detergents
and then analysed by 2-DE (Srisomsap et al., 2007). A greater range of differentially
expressed proteins were found, with the CCA cell line being enriched in cytoskeletal
proteins and proteins involved in protein turnover.
The most important drawback of both these cell line studies was that the
comparison made was between models from two cancers (biliary and liver). Making
the distinction between HCC and CCA is a frequent clinical question. However,
important questions such as differences between tumour and normal tissue could
not be addressed.
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4.1.6 Aim
The aims of this section of the study were two-fold. Firstly to use 2D-DIGE to
compare proteomes between an immortalised cholangiocyte cell line and three CCA
cell lines to determine how different they were. Secondly, to assign identities to
differentially expressed proteins using MALDI-ToF/ToF mass spectrometry.
4.2 Methods
4.2.1 Lysis buffer preparation
The following were added to a sterile 50ml tube:
 7M urea (21.02g) (Sigma, Cat No. U6504)
 2M Thiurea (7.61g) (Sigma, Cat No. T8656)
 30mM Tris Base (0.18g) (Sigma, Cat No. T1503)
 4% CHAPS (2g) (Sigma, Cat No. C9426)
Using double distilled sterile water the above was made up to 50mls and placed on a
roller mixer for solubilisation.
4.2.2 Protein extraction from cell lines
Cell lines used for this section of the study were: H69, M213, SkChA1 and HUCC-T1.
H69 is an immortalised cholangiocyte, M213 is an intrahepatic CCA of Thai origin,
SkChA1 is an intrahepatic CCA of western origin and HUCC-T1 is an extrahepatic CCA.
Cells were cultured to sufficient quantities in tissue culture flasks as described (see
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section 3.2.1). Four biological replicates of each cell line were commenced preferably
from stored cells which were at different passage numbers. The total surface area
for each version of each cell line amounted to about 675 cm2 (9 x T75 flasks). Cells
were harvested when they reached approximately 80% surface confluence. Once
lifted, the cells were pooled into a centrifuge tube and washed 4 times with sterile
PBS to remove all traces of FCS, after which 4ml of lysis buffer containing a
mammalian general purpose protease inhibitor cocktail (GE Healthcare) was added.
Lysis was aided by agitation then the mixture was passed through a 5ml syringe
attached to a 21 gauge needle five times to shear any DNA strands. The samples
were then aliquotted into 1.5ml centrifuge tubes and centrifuged at 16,100g for 1
hour at 20oC. The supernatant was collected and both the pellet and supernatant
aliquots stored at -20oC until further use.
Thus, the starting material for the experiment consisted of four biological replicates
from each of the four cell lines (16 preparations in total).
4.2.3 2-D clean up
Samples were purified and concentrated, by treating with a 2-D Clean-Up Kit (GE
Healthcare, Cat No. 80-6484-51).  The intention of this step was to reduce impurities
such as nucleic acids, salts and buffers. A protein sample in 280µl of lysis buffer was
added to 840µl of precipitant and incubated on ice for 15 minutes. A further 840µl of
co-precipitant was added and mixed. Samples were then centrifuged at maximum
speed for 5 minutes. The supernatant was removed, the samples centrifuged again
and the remaining supernatant aspirated. A layer of 40µl of co-precipitant was
added to each sample and left on ice of 5 minutes. Samples were centrifuged for 5
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minutes at maximum speed and then the wash was removed and discarded. Samples
were dispersed in 25µl of de-ionised water and then mixed with 1ml of wash buffer.
After 30 minute incubation at -20oC they were centrifuged for 5 minutes and the
supernatant removed and discarded. The remnant protein pellet was re-suspended
in pre-prepared lysis buffer.
4.2.4 Determination of protein concentration
It is crucial in 2D-DIGE that the protein concentration of each sample is identical.
Concentrations and total protein yield were measured on a Nanodrop
spectrophotometer (Thermo Scientific) using the Pierce 660nm protein assay
(Thermo Scientific, Cat No 22660) against standards consisting of albumin also
solubilized in lysis buffer. The Nanodrop software automatically calculates sample
concentrations. One µl of sample was mixed with 15µl of Pierce 660. Readings were
performed 50 minutes after mixing. Protein concentrations were then adjusted to
1283 µg/ml (the concentration of the most dilute sample) by adding more lysis
buffer and then reassessed to ensure that they are all the same.
4.2.5 Sample Labelling
The pH of each sample was established using pH 7.5 - 9.5 indicator strips and
adjusted to pH 8.5 using 50mM NaOH. An aliquot containing 50 µg protein from each
sample was then labelled with 400 pmol Cy5 DIGE Fluor minimal dye (GE Healthcare)
according to the manufacturer’s protocol. An internal standard was made by pooling
50 µg of each sample (800 µg in total), then labelled it with 6.4 nmol Cy3 (also GE
Healthcare). The labelling reactions were carried out on ice for 30 min then
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terminated by adding 1 ml of 10 mM lysine per reaction. Sixteen sample mixtures
were then prepared, such that each mixture contained a mixture of a 50 µg Cy5-
labeled sample and 50 µg of the Cy3-labeled internal standard (100 µg in total).
All 16 samples had been processed simultaneously up to this point.
4.2.6 2D-DIGE experimental design
Although it would be ideal for the 2-DIGE of all 16 samples to be carried out
simultaneously to ensure absolute reproducibility, this was not possible because the
maximum number of samples that the IEF and gel electrophoresis equipment can
handle simultaneously is twelve. Therefore, it was necessary to split the work into
two batches of eight samples, with the second batch running a day behind the first.
To avoid batch effect, each set of eight samples consisted of two replicates from
each cell line.
4.2.7 Quality assessment
In order to establish that the extraction process and the sample clean-up had been
successful and to maximise the chances of success for the forthcoming isoelectric
focussing, gel casting and gel electrophoresis, two quality assessment (QA) tests
were carried out. Each QA test used 100 µg of an unlabelled sample and one of the
gels from each casting. The only divergence from the forthcoming protocol is that
because the QA test samples were not fluorescently labelled the gels were visualised
by removing them from their glass plates and staining them with Coomassie Biosafe
stain (BioRad) as per the manufacturer’s protocol.
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4.2.8 Gel casting
Gels were prepared in a 2DE Optimizer (NextGen Sciences), which casts twelve 24
cm gels simultaneously to ensure homogenicity. The Optimizer was programmed to
cast gels with an acrylamide gradient of 9 to 16% as previous work had
demonstrated that this gradient provides a good separation of proteins from 5-200
kDa. The reagents used were as follows: 692ml of double distilled water, 258 ml of
Acrylamide 37.5:1 solution, (Sigma Cat No. 01709), 59ml of ammonium persulphate
1% wt/vol (Sigma Cat No. A9164), 157 ml of Glycerol 60% vol/vol (Sigma, Cat No
G5516), 44ml of TEMED 1% vol/vol (Sigma Cat No. T9281) and 157 ml of Tris-SDS
solution (2.25M Tris at pH 8.8 and 0.6% SDS). The Tris SDS was made up of Trizma
base (230.85g/l, Sigma Cat No. T1503), Tizma HCL (55.35g/l, Sigma Cat No. T3253)
and SDS (6.0g/l Sigma Cat No. L4390).
Gels were cast in low-fluorescent glass plates using an Ettan Dalt Twelve gel caster
(both GE Healthcare), with the casting volume programmed so that the gel mixture
filled the gap between the plates but leaving a 2cm gap at the top. This space was
filled with a 0.5% SDS gels solution and the gels were then left overnight to
polymerize at 4°C.
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4.2.9 Isoelectric strip rehydration
Each sample (now mixed with the internal standard and labelled) was mixed with
rehydration solution (8M urea, 2% CHAPS, 280mM DTT, 0.05% bromophenol blue
and 0.5%, pH 3-11 IPG buffer (GE Healthcare)) to make a final volume of 450 µl. This
was pipetted evenly along the length of a 24 cm, individual ceramic strip holder,
between the electrodes. A 24 cm, pH 3-11 non-linear Immobiline Drystrip (GE
Healthcare, cat 17-6003-77) was gently laid on top of the sample and then covered
in Immobiline DryStrip Cover fluid (GE Healthcare, Cat No. 17-1335-01). The strip
holder’s cover was replaced and the strips were left overnight in the dark for passive
rehydration.
4.2.10 Isoelectric focussing
Two paper wicks (BioRad, Cat No. 1654071) soaked in 20µl of ddH2O were placed
between the electrode poles of the IEF strip and the strip holder. The strip holders
were then placed onto the bed of an Ettan IPGPhor 3 isoelectric focussing system
(GE Healthcare) and IEF carried out according to the following protocol: 500V for 1
hour, 1000V for 1 hour, 8000V for 5 hours, 8000V for 70000Vh and 500V until
discontinuation. As described above, eight strips were focussed simultaneously.
4.2.11 Sample reduction and alkylation
Immediately following IEF the strips were removed from their holders and soaked for
15 mins in 4 ml of equilibrium solution (6M Urea, 75mM Tris pH8.8, 30% glycerol, 2%
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SDS and 0.01% bromophenol blue) containing 1% DTT and then for a further 15 min
in equilibrium solution containing 4% iodoacetamide.
4.2.12 Gel electrophoresis
Immediately following equilibration the SDS solution was aspirated from the top of
the gels and each IEF strip slotted into the space. A stainless steel spatula was used
to ensure no air bubbles were visible at the strip/gel border. A 1% molten agarose
solution was pipetted onto the strip, ensuring a good seal. The gels were then loaded
into an Etttan Twelve Gel Electrophoresis system (GE Healthcare) filled with TGS
(Tris/Glycine/SDS) running buffer (BioRad, Cat No 161-0772). Electrophoresis was
carried out at 15W for 1 hour followed by 180W until the bromophenol blue dye ran
to the bottom of the gel.
4.2.13 Image acquisition
The gels were preserved at 4oC in a dark enclosure until scanning. They were imaged
on a Typhoon Trio laser scanner (GE Healthcare). Scanning was performed whilst the
gel remained between its glass plates to prevent drying and shrinkage. Cy3 scanning
was performed at 532 nm excited fluorescence and Cy5 at 633 nm. A preliminary
quick and low resolution (1,000 μm pixel size) scan was performed to adjust the PMT
power (in Volts) and bring the darkest spots to between 70 and 80,000 (arbitrary
units). The purpose of this is to bring the highest intensity signals into the linear
range of the instrument. Once the power setting was determined, gels were scanned
at 100 μm pixel size resolution and were saved in .gel format.
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4.2.14 Gel analysis
Analysis was performed using the Progenesis Same Spots© software, v. 4.0
(Nonlinear Dynamics). A reference gel was selected on the basis of the best Cy3
(internal standard) image in terms of spot differentiation and gel distortion. All
fifteen other Cy3 images were aligned to this reference. Gel-matching was carried
out manually by placing approximately 150 anchor spots per gel. Then, the
automatic alignment function of the software was used for the remaining spots. The
software’s ‘transition view’ window was used as a quality check prior to accepting an
automatic alignment. Each automatically-matched spot was inspected individually
using the software’s 2 and 3 dimensional montage function. The split, merge and
delete functions were used to correct the minor inaccuracies performed by the
automatic function of the software.
Spot matching between the gels is straightforward because it is carried out using the
Cy3 internal standard which is identical on each gel. As the internal standard is made
from all of the samples in the experiment, every spot on every gel will be
represented in it, and because the Cy3 and Cy5 fluorophors have the same molecular
mass and charge, the Cy5 sample spot will have exactly the same coordinates in each
gel as its equivalent Cy3 reference spot. Therefore, once the internal standard spots
have been matched between the gels, the Cy5 sample spots are also matched.
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4.2.14.1 Gel normalisation
After spot matching, normalisation was performed to calibrate data between
different gels. Experimental variation, such as sample quantity, sample labelling and
gel image capture can affect abundance measurement. This variation was
normalised by comparing the intensity of the internal standard on each gel to the
reference gel, thus giving a gain (or loss) factor. The sample measurement can then
be adjusted by multiplying the results by this factor. This function is performed
within SameSpots software.
Figure 4-1 Same Spots 3 dimensional analysis
Each spot in the gel represents a different protein, with the protein’s expression level determining
the spot’s volume. By comparing the volumes of every spot in every gel, differences in protein
expression between the cell lines are established.
Once spot matching had been completed, the spots were ranked according to the
greatest fold-change across the groups at 95% confidence level. Spots that were
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differentially expressed in any of the cell lines compared with any other cell line
were identified by the software and ranked by p-value from one way ANOVA
analysis.
Figure 4-2 Example of a differentially-expressed spot from Same Spots software.
The highlighted spots in the two gels have been matched so they represent the same protein from
two cell lines. The spot in the right-hand image (HUCC cells) has a greater volume than the left hand
image (H69 cells) as it stains more heavily; therefore, the protein is expressed at a higher level in
HUCC than H69. In order to assign an identity to the spot it must be cut from the gel and analysed
by mass spectrometry.
Figure 4-2 illustrates an example of spot matching as processed by Same Spots. Two
matched spots with different intensities (i.e. spot volumes) can be seen. After
MALDI-MSMS analysis this spot (spot no 52) was identified as the protein
lactoylglutathione lyase. The image on the left is derived from protein from H69
cells, whist the one on the right from HUCC cells. It can be seen that the intensity of
the spot on the right is more intense, and this difference was calculated as
statistically significant taking all four biological replicates into account.
4.2.15 Preparative gels for mass spectrometry
As each of the gels used for the analysis “only" contained 100 µg of protein, four
preparative gels were made (one for each cell line), each of which contained 500 µg
of protein. These much higher protein loads significantly increase the chances of
gaining protein identities by mass spectrometry. Samples were prepared as
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previously described, except the total voltage for IEF was increased by 20% to allow
for the increased protein load: 500V for 1,500Vh, 1,000V for 800Vh, 10,000V for
16,500Vh, 10,000V for 26,640Vh and then 500V until discontinuation.
After electrophoresis, the gels were removed from their glass plates, fixed for 2
hours in a 40% methanol, 10% acetic acid solution then stained with Biosafe
Coomassie (BioRad). The gels were imaged using a Fujifilm LAS-3000 imager and the
differentially expressed spots identified by matching the spot patterns from the
preparative gels to those from the SameSpots images.
4.2.16 Excising spots
Spots identified as differentially expressed were cut from the preparative gel using a
spot picker (Gelcompany). If the spot was small and well circumscribed, a 1.5mm
diameter spot picker was used whilst if the spot was larger a 3.0 mm one was used.
Gel pieces were placed in individual protein low binding eppendorf tubes
(Eppendorf, cat no 022431081) preserved in 400µl of gel fixative solution (40%
methanol, 10% acetic acid) and assigned a Spot Number.
4.2.17 Preparing spots for MALDI=ToF/ToF analysis
The fixative solution was carefully removed and each gel piece and washed with
100µl of 25mM ammonium bicarbonate. Each sample was then washed twice in
100µl 25mM ammonium bicarbonate in 50% (v:v) which was then replaced with
100% aqueous acetonitrile. After 5 mins the acetonitrile was removed and the
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sample was dried in a vacuum concentrator for 20 minutes (ThermoSavant SC210A
SpeedVac Plus).
Trypsin was used to digest the protein samples. Trypsin was prepared as follows: an
aliquot of 100µl of Trypsin Buffer as supplied by the manufacturer (Promega, Cat No
608-274-4330) was added to 20µg of sequencing grade modified porcine trypsin
(Promega Can no V511A) to make stock trypsin solution. This was then diluted 1:4 in
25mM ammonium bicarbonate to make the working concentration of 0.02µg/µl.
Each sample was covered in 10µl of trypsin and allowed to re-swell for 5-10 minutes.
In the event that the trypsin did not cover the whole gel piece, a topping of 10µl of
25mM ammonium bicarbonate was added. The digests were incubated at 37oC
overnight.
A 1µl aliquot of each peptide mixture was applied directly to the ground steel MALDI
target plate, followed immediately by an equal volume of a freshly prepared matrix
solution (5 mg/ml solution of 4-hydroxy-α-cyano-cinnamic acid (Sigma) in 50%
aqueous (v:v) acetonitrile containing 0.1% , trifluoroacetic acid (v:v)).
4.2.15 MALDI-ToF/ToF mass spectrometry
Positive-ion MALDI mass spectra were obtained using an Ultraflex III MALDI-ToF/ToF
mass spectrometer (Bruker Daltronics). MS spectra were acquired over a mass range
of m/z 800-4000, externally calibrated against an adjacent spot containing 6 peptides
(of 904.681, 1296.685, 1750.677, 2093.086, 2465.198 and 3657.929 Da)
For each spot, the ten strongest PMF peaks with a signal-to-noise ratio > 30 were
selected for MS/MS fragmentation. Bruker flexAnalysis software (version 3.3) was
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used to perform the spectral processing for both the MS and MS/MS
spectra.Tandem mass spectral data were submitted to database searching using a
locally-running copy of the Mascot program (Matrix Science Ltd., version 2.3),
through the Bruker ProteinScape interface (version 2.1). The search parameters used
were: Enzyme, Trypsin; Fixed modifications, Carbamidomethyl (C); Variable
modifications, Oxidation (M); Peptide Mass Tolerance, 250 ppm; Fragment Mass
Tolerance, 0.5 Da; Instrument type, MALDI-TOF-TOF. Identities were sought against
the IPI Human database (version 3.87). IPI human is a database of human proteins,
currently consisting of > 90,000 minimally redundant yet maximally complete
proteins (one sequence per transcript) selectively-sourced from other databases
such as SwissProt and Trembl (Kersey et al., 2004). The search criteria allowed for
Carbamidomethyl (C) as a fixed peptide modification and oxidation (M) as a variable
modification. One missed tryptic cleavage was allowed for and the mass tolerances
were 250 ppm (MS) and 0.5 Da (MSMS).
Only spot identities with a total ion score of over 95% were accepted.
All proteomic work was carried out by me under laboratory supervision of Dr William
Mathieson (Imperial College London). Mass spectrometry was carried out at the
University of York's Centre of Excellence in Mass Spectrometry under the supervision
of Adam Dowle (University of York).
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4.3 Results
4.3.1 Test Gel I
The first 24cm test gel demonstrated horizontal spot-streaking in the basic region of
the gel.
Figure 4-3 M213v2, 24 cm gel.
As the streaking was horizontal it shows that the IEF of the proteins had not been
successfully completed. As the streaking is restricted to the basic region of the gel it
was likely to be related to the random re-formation of disulphide bonds in the basic
proteins only.  DTT was incorporated into the buffer prior to IEF to cleave disulphide
bonds. However, DTT can migrate from the basic regions of the IEF strip during
focussing, enabling the disulphide bonds to reform randomly, leading to this
pH11pH3
Increasing
molecular
mass
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streaking pattern in the basic region. To test this hypothesis two test gels were (see
section 4.3.2) carried out, one with an alkylation step so that reactive cysteine
groups will be capped prior to IEF and unable to reform disulphide bonds.
4.3.2 Test Gel II
Figure 4-4 M213v3, 7cm gel, without Reduction/Alkylation step Cy5
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Figure 4-5 M213v3, 7cm gel, with Alkylation/Reduction step Cy5
4.3.3 Gel electrophoresis and analysis
The SameSpots automatic spot-detection software identified a total of 1380 spots in
the gels. However, on manual inspection it became apparent that some spots
identified as single actually represented two or more individual spots. These were
split manually using the relevant software function. The software misinterpreted
some artefacts such as folds or specks on the gel as spots; these were manually
deleted. A few larger spots were identified as more than one individual spot and
were manually merged. After the above process, the study identified a total of 1110
spots that were considered genuine.
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Although the normalized volume of each spot varied between gels, all 1110 spots
were detected in all of the gels. Initially, comparisons were made between the
different cell lines. Hence, although there was inter-sample difference in the level of
protein expression there were no instances where a protein was detected in one cell
line but not in another. Cell line H69 was taken to be the reference cell line,
representing normal cholangiocytes.
In order to compare the spot patterns between cell lines, the normalized spot
volume for each spot was averaged by one-way ANOVA and any spots in any cell line
compared with H69 with a statistically different volume were highlighted. Each of
the three CCA cell lines was compared to the reference cell line for number and
magnitude of difference. Scatter plots were generated to illustrate the distribution
of gel spots, for the complete proteome and for selected spots deemed to be
significant in the analysis. In the ANOVA analysis, a p value of <0.01 was used as a
threshold for significance.
4.3.3.1 Comparison of H69 and HUCC cell lines
When compared to H69, the HUCC cell line, representing intrahepatic
cholangiocarcinoma, had 168 spots that were expressed differently at a statistically
significant level. Of these 100 (9.01%) were up regulated and 68 (6.13%) were down
regulated. A total of 942 (84.86%) spots were not different to a statistically
significant level.
The above figures only represent the numbers of spots and no distinction in terms of
protein abundance is accounted for. Therefore analysis of the volume of the
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differentially expressed spots was performed. In terms of spot-volume, the up
regulated proteins in HUCC represented 10.98% of the total proteome, whilst the
down regulated ones 4.84%.
Figure 4-6 is a scatter plot plotting the normalised volume of the all individual spots
for H69 and HUCC. The Pearson correlation coefficient (r value) was calculated at
0.05785 with a p value of 0.0540 using Microsoft Excel 2010. The r value suggests
that there is no correlation; however, this is not statistically significant.
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Figure 4-6 H69 v HUCC Scatter plot of all 1110 spots identified
Figure 4-7 is a scatter plot of the 168 differentially expressed spots. Spots lying above
the x=y boundary (dotted line) represent up regulation in HUCC compared to H69
whilst those below represent down regulation. Visual inspection suggests that more
spots are up regulated than down regulated (100 vs 68).
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Figure 4-7 H69 v HUCC, scatter plot of differentially expressed spots
4.3.3.2 Comparison of H69 and SkChA1 cell lines
In cell line SkChA1, 293 spots were differentially expressed. Of these, 189 (17.03%)
were up regulated and 104 (9.37%) were down regulated. There were 817 (73.60%)
spots that were not differentially expressed. The up regulated proteins represented
24.51% of that cell line’s proteome volume and the down regulated ones
represented only 6.20% of the total volume. The r value in this comparison was
-0.3664 with a p value of < 0.0001. This r value suggests a better correlation than
that of HUCC. The p value confirms that this is also to a statistically significant level.
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Figure 4-8 H69 v SkChA1 Scatter plot of all 1110 spots identified
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Figure 4-9 H69 v SkChA1, scatter plot of differentially expressed spots
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4.3.3.3 Comparison of H69 and KKU M213 cell lines
In cell line M213, 184 spots were differentially expressed. Of these, 119 (10.72%)
were up regulated and 65 (5.86%) were down regulated. There were 926 (83.42%)
spots that were not differentially expressed. The up regulated proteins represented
13.75% of that cell line’s proteome volume and the down regulated ones
represented only 4.20% of the total volume. . The r value in this comparison was
-0.1667 with a p value of < 0.0001. This r value suggests a stronger correlation than
that of HUCC but not as strong as that of SkCHA1.
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Figure 4-10 H69 v KKU M213 Scatter plot of all 1110 spots identified
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Figure 4-11 H69 v KKU M213, scatter plot of differentially expressed spots
4.3.4 Gel spot picking
A total of 96 differentially-expressed spots were visualized in the preparative gels
and excised for MALDI-MSMS analysis. Of these, 74 spots were harvested from a gel
prepared using cell line M213, 7 from cell line SkChA1 and 14 from H69. There was
overlap of 5 spots giving a total of 91 unique spots with 5 replicates (see Figure
4-12).
The table below summarises the number of differentially expressed spots and their
significance in the cell line comparisons. Spots were picked manually, (see section
4.2.16) so they had to be visible to the naked eye. Image acquisition using a laser
scanner with subsequent software analysis (see section 4.2.13) has a superior
sensitivity and resolution to the naked eye inspection of the gels. It is estimated that
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Coomassie blue, used in staining proteins can detect about 25% of proteins detected
in DIGE (Patton, 2002). Having said that, it is generally accepted that if a protein spot
cannot be visualised by Coomassie-blue staining it is unlikely to yield sufficient
protein for a MALDI-derived identity. As a result only 96 of the proteins detected
were eventually picked for identification by MALDI.
Number of differentially
expressed spots
No of spots picked and
analysed by MALDI
No of IDs
obtained
Up regulation in all 3 cell lines 26 10 6
Down regulation in all 3 cell lines 8 1 1
Up regulation in HUCC and SkChA1 33 9 4
Down regulation in HUCC and SkChA1 8 2 2
Up regulation in HUCC and KKU M213 7 1 1
Down regulation in HUCC and KKU M213 7 3 2
Up regulation in SkChA1 and M213 31 1 1
Down regulation in SkChA1 and M213 9 2 1
Up regulation in HUCC only 37 2 2
Down regulation in HUCC only 28 4 3
Up regulation in SkChA1 only 56 4 4
Down regulation in SkChA1 only 98 13 12
Up regulation in KKU M213 only 29 6 6
Down regulation in KKU M231 only 43 4 2
Down regulation in HUCC and SkChA1, up in M213 1 0 -
down regulation in HUCC, up regulation in SkChA1 1 0 -
Down regulation in HUCC, up regulation in SkChA1 and M213 1 0 -
Down regulation in SkChA1, up regulation in KKU M213 10 1 1
Up regulation in HUCC and SkChA1 but down regulation in KKU M213 1 1 1
Up regulation in HUCC down regulation in KKU M213 6 0 -
Up regulation in SkChA1 down regulation in KKU M213 5 3 3
Table 9 Protein expression as compared to H69 cell line
The figures that follow illustrate the gels used for spot picking including the locations
of each of the 96 spots that were picked.
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Figure 4-12 Spots (74 in total) harvested from a gel prepared using cell line M213
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Figure 4-13 Spots (6 in total) harvested from a gel prepared using cell line M213
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Figure 4-14 Spots (15 in total – some replicates) harvested from a gel prepared using cell line
SkChA1
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MALDI TOF/TOF and database analysis generated confident identities for 52
proteins. Each identity was scrutinised in detail separately and was only accepted as
genuine if the Mascot protein score was sufficiently high to be confident that the
identity is genuine at 95% confidence interval and > 1 peptide was fragmented to
obtain that identity. In cases where only one peptide had been fragmented the
protein’s identity was only accepted if the spot on the gel was at the appropriate
place (i.e. the charge and molecular weight were correct). Some proteins were
detected more than once, so the different spots represented isoforms of the protein.
Overall, the total number of unique proteins was 29, listed in Table 10.
Protein identity IPI human
accession
number
No of
peptides
Mascot
Protein
score
HUCC SkChA1 KKU M213
14-3-3 protein sigma IPI00013890 3 256 + o +
ACTB Actin, cytoplasmic 1 IPI00021439 3 289 o - o
Alpha-enolase IPI00465248 5 348 o - o
Alpha-enolase IPI00465248 3 143 o + -
Annexin A2 IPI00418169 3 186 + + +
Annexin A2 IPI00418169 6 494 + + o
ATP synthase subunit beta, mitochondrial IPI00303476 9 789 + o o
Calmodulin IPI00075248 5 373 o - o
Calreticulin IPI00020599 3 216 - o -
Calreticulin IPI00020599 1 90 o o +
Complement component 1 Q subcomponent-binding
protein, mitochondrial
IPI00014230 2 147 - - o
Elongation factor 1-delta IPI00023048 2 163 o o +
Endoplasmin IPI00027230 9 635 o o +
Endoplasmin IPI00027230 9 635 o + -
Endpolasmin IPI00027230 9 635 o + +
Galectin-1 IPI00219219 2 131 o o +
Gamma-synuclein IPI00297714 3 317 o + o
GAPDH IPI00219018 3 338 - o o
GAPDH IPI00219018 3 286 o - o
Heterogeneous nuclear ribonucleoprotein A1 IPI00215965 7 363 - - o
HSPA8 Isoform 1 of Heat shock cognate 71 kDa protein IPI00003865 6 506 o - o
Isoform 2 of Annexin A2 IPI00418169 5 285 + + o
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Lactoylglutathione lyase IPI00220766 1 96 + + -
Nucleophosmin IPI00220740 1 106 - - -
Nucleophosmin IPI00220740 1 110 o - -
Nucleophosmin IPI00220740 1 99 o + o
Nucleophosmin IPI00220740 3 323 o O -
Nucleoside diphosphate kinase B IPI00026260 4 261 o - O
Peroxiredoxin IPI00027350 2 167 o - O
Prostaglandin E synthase 3 IPI00015029 2 178 + + O
Protein S100-A6 IPI00027463 1 87 + + O
Protein SET IPI00072377 2 180 o + O
PSME2 IPI00384051 3 172 o - O
Rho GDP-dissociation inhibitor 1 IPI00003815 5 334 o + -
Thioredoxin IPI00216298 4 247 o o +
Translationally controlled tumour protein II IPI00009943 3 258 + + +
Tubulin alpha-1C chain IPI00218343 5 313 o o -
Tubulin alpha-1C chain IPI00218343 7 723 o + O
Tubulin beta-2C chain IPI00007752 6 477 - o -
ubiquitin IPI00179330 2 92 o - +
o: no difference, -:down regulated, +: up regulated
Table 10 Summary of identified proteins
4.4 Discussion
The selection of cell lines for this study was made on the following basis: H69, a cell
line derived from immortalised normal cholangiocytes would act as a control. The
selection of cholangiocarcinoma variants represents pathologically distinct
cholangiocarcinoma subtypes : one derived from a patient with intrahepatic disease
(HUCC-T1), one from an extra hepatic (SkChA1) and one derived from a patient who
suffered from the Far Eastern intrahepatic variety (M213).
Protein from cell lines is relatively inexpensive and easy to harvest and in theory can
provide an unlimited supply. Furthermore it is relatively homogenous with none of
the between-sample differences that characterize clinical material. Consequently,
the decision was made to proceed with four biological replicates (i.e. different
passage numbers) of each of the four cell lines. Hence, 16 gels were run in total in
order to add power to the statistical significance of the findings.
4.4.1 Alpha enolase
Enolase is a protein with a mass between 82 and 100 kDa, depending on the isoform.
It is a glycolytic enzyme and responsible for catalysing the conversion of 2-
phosphoglycerate to phosphoenolpyruvate in the Embden Meyerhof Parnas
glycolysis pathway. In humans, 3 enolase isozymes can be found, which are tissue-
specific: alpha, beta and gamma enolases. Alpha enolase (enolase 1) is found in
many tissues but mostly in the liver while beta enolase is abundant in muscles and
gamma enolase (often referred to as neuron specific enolase) is exclusively found in
neuronal tissue (Pancholi, 2001).
The proteomic analysis of cholangiocarcinoma cell lines
162
The presence of high glucose metabolism (and by consequence glycolysis) in cancer
is exploited in routine clinical practice today through the use of fluorodeoxyglucose
positron emission tomography (FDG-PET). This observation, often referred to as the
Warburg effect, was first recognised in 1920 (Bensinger and Christofk, 2012).
Although enolase forms but one link in the glycolysis cascade, expression levels of its
three isoforms in cancer have been widely investigated. Over-expression of alpha
enolase has been reported in many cancers including lung, breast, colorectal and
hepatocellular cancer.
Takashima et al analysed the proteomes of 26 samples from hepatitis C associated
HCC patients and reported an association of alpha enolase levels with hepatocellular
tumour progression and with poor prognostic features such as tumour size and
tumour vascular invasion (Takashima et al., 2005). The group championed the use of
this protein as a prognostic biomarker.
Three years later, the same group analysed specimens from 60 patients who had had
liver resections for HCC with curative intent. Samples were analysed using arrayCGH
(a technique that quantifies genomic aberrations). They showed that a variety of
glycolysis related genes were up regulated, including alpha enolase. High levels of
this enzyme, however, clustered to a subgroup of patients who had a worse
prognosis and less overall survival (Hamaguchi et al., 2008). The authors went on to
suggest that apart from acting as a potential biomarker, alpha enolase could provide
a suitable oncological target in view of its differential expression but more
importantly in view of its specificity to liver tissue. This tissue specificity,
hypothetically at least, could minimise the side effects of targeting the enzyme. They
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therefore had an in-vitro arm to their study where an HCC cell line (HLE) was
exposed to siRNA (small interfering RNA) inducing a transient knockdown of alpha
enolase transcription. This transfection resulted in a marked decrease in both the
mRNA and protein levels of alpha enolase and significantly inhibited the proliferation
of this cell line. This was observed in both a glucose rich and glucose depleted
environment. Cell cycle analysis showed that cells remained in the pre-mitotic phase
(G2).
With respect to CCA the only publication relating to alpha enolase levels was
published in 2012 by Yonglitthipagon et al (Yonglitthipagon et al., 2012). This study
performed a proteomic analysis of various CCA cells, one of which was KKU M213.
Their results showed that alpha enolase was up regulated in all CCA cell lines
including KKU M213 when compared to the H69 cells. This study also performed
immunostaining on 301 paraffin embedded samples from patients with resected CCA
to determine alpha enolase expression. Patients, whose cancers expressed high
levels of alpha enolase, had significantly poorer survival rates than patients with low
expression.
I have identified 6 differentially expressed spots corresponding to alpha enolase
(spots 12, 15, 16, 17, 18 and 19). Their gel location shows that all six are on the same
horizontal line indicating that the isoforms have the same molecular mass but
different charges. These post translational modifications are probably caused by
events such as methylation, acetylation and phosphorylation rather than
glysosylation (which would alter the molecular mass). Five of the six spots, however,
were down regulated in SkChA1, a cell line harvested from a western patient with EH
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CCA. Exactly why this result contradicts some of the findings in the published
literature is not obvious. Certainly, there are studies where alpha enolase has been
shown to be down regulated, but these were in other cancers, namely HCC and non-
small cell lung cancer (Kim et al., 2003, Chang et al., 2003). Another factor that
should be considered is the patient profiles used in the quoted studies.
Yonglitthipagon et al studied alpha enolase expression exclusively in patients from
the Far East with intrahepatic CCA. SkChA1 is a cell line derived from a patient with a
very different profile.
One of the six spots corresponding to alpha enolase (spot 18), was down regulated in
cell line KKU M213 whilst up regulated in SkChA1 as compared to H69. This
contradicts the findings of Yonglitthipagon et al (2012) who reported up regulation
of alpha enolase in this particular cell line. The culture technique for this cell line was
the same in both studies, however, the methodology for protein analysis differed
considerably. Yonglitthipagon et al used 2 dimensional polyacrylamide gel
electrophoresis (2D PAGE) with 7cm IPG strips. This technique allows for a greater
margin of error than DIGE on 24 cm IPG strips as used in this study. Standard 2D
PAGE requires multiple technical replicate gels to allow for gel-to-gel variation when
comparing samples, as only one sample can be run on each gel. However, in DIGE,
each sample is compared with a common internal standard that has been run on the
same gel (but labelled with a different dye). Thus, experimental variations such as
gel-to-gel differences become irrelevant. Also, our use of the common and identical
internal standard also allows for more accurate spot-matching between the gels.
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Finally, our use of 24cm (instead of 7cm) gels allows for a much improved resolution
both in imaging and in spot picking.
Apart from its cytosolic function as a glycolytic enzyme, it is becoming increasingly
evident that alpha enolase can also act as a cell membrane receptor. In head and
neck cancer and non-small cell lung cancer it functions as a strong plasminogen-
binding receptor enhancing local fibrinolysis and contributing to tumour invasion
(Tsai et al., 2010, Chang et al., 2006). It is possible that only the intracellular isoform
was solubilizable in the lysis buffer so no comment can be made on the role of alpha
enolase as a cell membrane receptor in CCA cells lines.
4.4.2 Annexin A2
Annexins are intracellular proteins, classified into 5 groups: A to E. Only group A is
found in mammals and consequently humans. They participate in a diverse range of
physiological activities including signal transduction, anticoagulation, endocytosis
and exocytosis, anti-inflammatory, cell proliferation, differentiation and apoptosis.
There are 12 subcategories of annexins found in humans, annexin A1 to A11 and
annexin A13. The annexin A2 protein, encoded by the ANXA2 gene, can exist as a
monomer, heterodimer or heterotetramer with protein p11, a member of the S100
group of proteins. Annexin A2 fulfils different biological functions which depend on
which of the above forms it takes. The monomeric form is mostly distributed in the
cell cytoplasm, nucleus and extracellular surface whilst the heterotetrameric form
forms a common receptor for tissue type plasminogen activator (Zhang et al.,
2012b).
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Annexin A2 has multiple functions. It has a role in membrane structure, membrane
transportation, exocytosis and signal transduction. It is also involved in cell
proliferation, cell differentiation and apoptosis (Chiang et al., 1999).
Accumulated evidence has identified annexins as protagonists in neoplasia. Much of
the focus has been on their role as diagnostic and prognostic markers, however,
their regulation as a potential therapeutic target is also gaining favour.
By simple association, annexin A2 has been shown to have altered levels in most
common cancers. It is up regulated in colorectal, breast, renal cell, hepatocellular
and pancreatic cancers (Ji et al., 2009). It is also down regulated in prostate cancer,
oesophageal squamous carcinoma, nasopharyngeal carcinoma and sinonasal
adenocarcinoma (Zhang et al., 2012b).
Tian et al, used 2 dimensional gel electrophoresis (2 DE) to look at differentially
expressed proteins in pancreatic cancer (Tian et al., 2008). They compared 8 samples
from fresh tissue (stored at -80oC) pancreatic ductal adenocarcinoma with normal
adjacent pancreatic tissue. They identified 30 spots of interest which were analysed
by tandem mass spectrometry. Annexin A2 was up regulated in all the cancer
samples.
Yu et al, analysed fresh samples from 40 patients with resected HCC by cDNA
microarrays. All tumour samples expressed higher levels of annexin 2, when
compared to normal liver tissue acquired at the same resection (Yu et al., 2007). Two
years later, the same group published a further study where RNA levels were
scrutinised. Annexin A2 expression levels were again significantly higher in 40 HCC
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samples when compared to adjacent normal liver tissue. The mean difference was a
2.44 fold increase in annexin A2. Furthermore, higher levels of annexin A2 were
associated with higher grade tumours. In the same study, the group analysed serum
samples from patients with HCC and compared these to serum taken from patients
with acute hepatitis, chronic hepatitis, patients with hepatic cirrhosis and normal
patients. An ELISA technique was used and showed that on average, annexin A2
levels were highest in the patients with HCC, followed by patients with cirrhosis. The
group with the lowest average was the one with normal controls. However, even
though each group had 55 to 86 patients there were some normal controls who had
higher levels of serum annexin A2 than HCC patients. Therefore this test is not
specific enough to be considered diagnostic (Ji et al., 2009).
The studies reporting annexin A2 levels in CCA are few, the most recent one coming
from the same group that reported high levels of alpha enolase in CCA and discussed
above (see section 4.4.1). Yonglitthipagon et al (2010) reported up regulated levels
of annexin A2 in two of the four cell lines investigated, one of which was KKU M213.
The methodology used was identical to the aforementioned one described in the
discussion of alpha enolase. Yonglitthipagon et al’s study also investigated samples
from 301 patients with IH CCA. Tissue microarray and immunohistochemistry were
used to determine expression changes of annexin A2 in normal bile duct,
hyperplastic bile duct and cholangiocarcinoma tissue. Biopsies from 76.2% of
patients stained positively for annexin A2. Staining positively for annexin A2 did not
correlate with tumour size or histological subtype, however, it correlated with poor
prognosis (Yonglitthipagon et al., 2010).
The proteomic analysis of cholangiocarcinoma cell lines
168
In my study, annexin A2 was up regulated in all three CCA cell lines when compared
to the cholangiocyte H69 cell line. This not only correlates with the study by
Yonglitthipagon et al (2010) in confirming that the KKU M213 expresses higher levels
of annexin 2, but it also reinforces the evidence that this protein is widely over-
expressed in CCA. Yonglitthipagon et al also suggested in their study that CCA caused
by the liver fluke Opisthorchis viverrini expresses high level of annexin A2. As there
are no studies investigating the expression of annexin A2 in patients with western
hemisphere variety of CCA, or patients with EH CCA, no reliable comment can be
made generally about annexin A2 and CCA. The results of my study strongly suggest
that annexin A2 is up regulated in all CCA, irrespective of location or aetiological
factor. This of course needs to be validated by further investigation of patient
samples.
The implications of identifying annexin A2 as a differentially-expressed protein in
CCA are not limited to biomarker discovery. In vitro and in vivo animal studies have
succeeded in regulating tumour proliferation by modifying annexin A2 expression.
Braden et al published a study in 2007 describing a novel combination agent active
against in vitro prostate cancer cells (Braden et al., 2007). The agent combined a
plasmid, which upon cellular transcription produces siRNA against annexin A2, with a
nanoparticle: poly(D,Llactide-co-glycolide) (PLGA). PLGA is a biodegradable and
biocompatible polymer, which undergoes slow intracellular hydrolysis releasing the
plasmid at a sustained rate. The same group followed up this study in 2009 by
exposing a prostate cancer mouse model to the same combination agent (Braden et
al., 2009). Nude mice were inoculated with the DU 145 prostate cancer cell line,
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producing a xenograft model. Following exposure with the above agent (agent was
directly injected into the tumour tissue), survival and tumour growth patterns were
favourable for the treated cohort. Annexin A2 levels (measured by qrtPCR) were
much lower in the treated group.
4.4.3 Protein 14-3-3 sigma
The 14-3-3 proteins, first identified in 1967, make up a family of highly conserved
acidic molecules. Their name, 14-3-3, refers to the elution and migration pattern of
these proteins on chromatography and gel electrophoresis. The 14-3-3 proteins
eluted in the 14th fraction of bovine brain homogenate and were found on positions
3-3 of subsequent electrophoresis (Aitken, 2006).
There are seven known mammalian isoforms (β, γ, ε, ζ, θ, η and σ) each encoded by
a different gene. 14-3-3 proteins self-assemble into homo and heterodimers, with
some family members preferring to homodimerize (sigma and gamma) and other
family members (epsilon) preferring to heterodimerize. The dimers can interact with
a diverse range of cellular proteins which include biosynthetic enzymes, cytoskeletal
proteins, transcription factors, signalling molecules, apoptosis factors and tumour
suppressors (Morrison, 2009). The interaction takes place at specific serine and
threonine residues and can result in: i) conformational change in the target molecule
or ii) masking or exposure of the functional shape that regulates the intracellular
localisation of the target molecule or iii) changes in the phospohorylation state or
stability of the target molecule.
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Several human diseases exhibit over or under expression of protein 14-3-3 in its
different isoforms. For example, elevated levels of 14-3-3 proteins are found in the
cerebrospinal fluid of patients suffering from Creutzfeldt-Jakob disease (Takahashi et
al., 1999). Of particular interest however, is that the sigma isoform has been linked
to a variety of cancers: breast, stomach, bladder, prostate and oral squamous cell
carcinoma.
Wu et al (2012) studied the expression of all the 14-3-3 protein isoforms in 86 CCA
patients. Using immunohistochemistry they quantified the level of expression and
compared the results to adjacent normal biliary tissue (Wu et al., 2012a). Most of
the 14-3-3 protein isoforms were up regulated in CCA. The sigma isoform correlated
positively with local lymph node and distal metastasis as well as poorer overall
survival.
My study demonstrated an up regulation of protein 14-3-3 in cell lines HUCC and
KKU M213. It is consistent with the findings of Wu et al (2012). Functionally, the
sigma isoform is associated with control of the G2/M checkpoint in the cell cycle. It is
part of the downstream signalling pathway of p53 and the action of the sigma
isoform is to promote apoptosis. Hence, it would be expected that up regulation of
this isoform would have the opposite effect to what Wu et al have reported, i.e. that
it would be a good prognostic marker. However, protein 14-3-3 sigma has also been
shown to have another effect, in inhibiting the pro-apoptotic proteins BAD and BAX
(Wu et al., 2012a). As discussed in section 3.4, apoptosis is a balance of pro and anti-
apoptotic signals. The imbalance described above could explain its role in CCA
tumourigenesis. This checkpoint imbalance could also be potentially exploited in
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cancer therapeutics. It has been suggested that by modifying the levels of 14-3-3
sigma, susceptible cells could be tipped into a pro-apoptotic route therefore
increasing the efficacy of chemotherapy, in a similar fashion to PK11195 (Samuel et
al., 2001).
4.4.4 Translationally controlled tumour protein
The translationally controlled tumour protein (TCTP) was first identified in the late
1980s. It has a molecular mass of 19kDa and is found in a wide range of eukaryotic
organisms, such as animals, plants and fungi, indicating that its evolutionary origins
lie in the distant past. TCTP is hydrophilic and its intracellular localisation is
predominantly in the nucleus and cytoplasm. TCTP is one of the 20 most abundantly
expressed proteins in normal cells and its function is described as “a heat stable,
calcium binding, antioxidant protein that negatively regulates apoptosis and causes
release of histamine from basophils” (Gnanasekar et al., 2009).
Although expression levels vary, it is expressed in hundreds of tissues (Bommer and
Thiele, 2004). Mitotically active tissues express higher levels of TCTP. Of the variety
of functions of TCTP, of most interest is its property of protecting cells from death.
Although exactly how this is achieved remains to be identified, several mechanisms
have been proposed:
TCTP is considered a chaperone protein. It can protect a variety of heat denatured
proteins such as lysozymes and luciferase (a bioluminescence protein) from thermal
or chemical shock effects. It is also over expressed in cells exposed to such stimuli
(Gnanasekar et al., 2009). By reducing this stress response, Nagano et al propose
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that TCTP protects cells from its pro apoptotic effects (Nagano-Ito and Ichikawa,
2012). TCTP is a calcium ion scavenger, again resulting in apoptosis inhibition. Finally,
TCTP can protect cells from hydrogen peroxide-induced oxidative stress and
subsequent apoptosis (Gnanasekar and Ramaswamy, 2007).
Of particular interest is that TCTP can protect cells from apoptosis induced by
cytotoxic agents such as treatment with etoposide and 5FU. It achieves this by
interfering with the Bcl-2 family of proteins (especially MCL-1 and Bcl-xL), readjusting
the apoptosis equilibrium in favour of cell survival (see sections 1.1.6 and 3.4) (Liu et
al., 2005). In addition TCTP can inhibit apoptosis through the p53 route. This is
achieved by TCTP binding to p53, destabilising the protein (Rho et al., 2011). It also
represses p53 transcription (Amson et al., 2012).
In my study, TCTP was over expressed in all three CCA cell lines when compared to
the immortalised cholangiocyte cell line H69. Srisomap et al did not show the same
result in their study of the HUCC cell line although they did show differential
expression in HCC cell lines (Srisomsap et al., 2004). None of the proteomic studies
on human CCA showed up regulation of TCTP in patient samples. It is clear, however,
that much research has been targeted at TCTP and its effect on other cancers.
Recently a group from France have patented an antisense oligonucleotide targeting
TCTPA mRNA and have shown its effect in preclinical studies (Baylot et al., 2012).
4.4.5 Nucleophosmin
Nucleophosmin, also known as nucleolar phosphoprotein B23 and numatrin, is a
ubiquitously expressed nuceolar phosphoprotein encoded by the NPM1 gene. It has
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a molecular weight of about 37 kDa and although it is mainly found in nucleoli it
shuttles between the nucleus and cytoplasm. Nucleophosmin is a multi-functional
protein involved in many cellular activities and has been related to both growth
promoter and growth suppressive roles (Grisendi et al., 2006). It is not surprising
therefore that it has been linked to the uncontrolled growth of cancer cells and
carcinogenesis although its exact role therein remains controversial.
Nucleophosmin is over or under expressed in various solid tumours. For example in
colorectal, gastric, prostatic, hepatocellular and ovarian carcinomas it is over
expressed and has been championed as a tumour marker (Grisendi et al., 2006).
On the other hand, reduced NPM protein expression was associated with poor
prognosis in a recent study on breast cancer (Karhemo et al., 2011). This study
included samples from 1160 patients with biobanked tissue core biopsies and with
follow-up data of approximately 9.5 years. Samples were examined by
immunostaining and q-RT-PCR. The lower the expression of nucleophosmin, the
poorer the prognosis (measured outcome was distant disease free survival).
My study showed 4 spots corresponding to nucleophosmin that were differentially
expressed amongst the different cell lines examined. All four had a strong Mascot
protein score indicating that they are reliable results and all corresponded to the
correct location for nucleophosmin on the electrophoresis gel. The overall
observation was that the expressed levels of nucleophosmin were less in tumour cell
lines than the control cholangiocyte. This observation corresponds with that of the
published study in breast cancer but not with other cancers mentioned. None of the
studies outlined in section 4.1.4 reported any variability in this protein.
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4.4.6 Complement component 1 Q subcomponent-binding protein,
mitochondrial
Complement 1q binding protein (also known as p32) is a 33kDa protein first
described in 1981. Currently there are conflicting reports regarding the function of
p32 and its potential role in the progression of cancer.
In an in vitro setting, Ithana et al 2008 demonstrated that p32 is an essential
mitochondrial mediator of apoptosis by binding to the ARF tumour suppressor
protein. Knockdown of p32 by siRNA, resulted in apoptosis inhibition (Itahana and
Zhang, 2008). In contrast, other studies have demonstrated a pro survival benefit
with increased levels of p32 and an overexpression of p32 in a variety of human solid
tumours, although not CCA (McGee et al., 2011).
Another interesting observation is that Kamal et al showed that p32 is required for
cisplatin-induced apoptosis (Kamal and Datta, 2006). Although our previous
experiments (see section 3.3.2.2.1) looked at the effect of cisplatin on all the cell
lines, these were done in a different context. Therefore comparisons cannot be
directly drawn between over or under expression of p32 in the cell lines and their
response to cisplatin monotherapy.
This study showed that p32 was down regulated in cell line HUCC and SKCha1 whilst
there was no significant difference between KKU M213 and the normal
cholangiocyte cell line.
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4.4.7 Endoplasmin
Endoplasmin, also known as Heat Shock Protein 90 B1 (HSP90B1) is a housekeeping
chaperone molecule with a molecular mass of 90kDa. It belongs to the larger family
of HSP90 proteins - one of the commonest expressed protein groups. Heat shock
proteins can aid cell survival by refolding and stabilizing stress-affected denatured
proteins. The cellular stresses include heat, lack of nutrients, hypoxia and in the case
of cancer cells, immunological mediated stress. The HSP90 proteins are able to
‘buffer’ cells from these stresses allowing them to survive in an otherwise
inhospitable environment (Grbovic et al., 2006, Takayama, 2003, Neckers and
Workman, 2012). Furthermore they are involved in signal transduction and other key
pathways of particular relevance in malignancy. HSP 90 is regarded as essential for
tumourigenesis and is over expressed in cancer cells (Neckers and Workman, 2012).
Being a housekeeper protein, HSP90 was initially dismissed by the pharmaceutical
industry as not a suitable target for cancer therapeutics, in view of the perceived
potential side effects and toxicity this approach might generate. However, following
work by academic non-profit organisations and the United States National Cancer
Institute,  this view has changed and at present 17 agents are at an advanced stage
of development by pharmaceutical companies and have entered clinical trials
(Neckers and Workman, 2012). To date, none have been licenced for use or
completed phase III trials and none have been on patients with CCA.
The expression of HSP90 in patients with CCA was recently investigated by a group in
Thailand (Boonjaraspinyo et al., 2012). Fifty frozen patient samples were analysed by
PCR and tumorous tissue was compared to adjacent normal tissue. There was up
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regulation of HSP90 in 76% of patients. When clinicopathological correlation was
performed there was no relation of HSP90 levels with patient survival.
Another group from Taiwan recently published a preclinical study of HSP90 inhibitor
action in CCA (Chen et al., 2012). Samples from 8 patients with intra hepatic CCA
samples were initially analysed for gene expression using microarrays. The results
were used to query the Broad Institute connectivity map, for identification of
potential active drugs. In the top 5 drugs returned, 3 were HSP90 inhibitors: 17-AAG
(tanespimycin), geldanamycin and alvespimycin. The researchers then exposed in-
vitro cell lines (one of which was HUCC-T1) to 17-AAG and NVP-AUY922. They also
exposed a rat CCA model (chemical induced CCA) to NVP-AUY922 treatment. They
observed that both HSP90 inhibitors caused inhibition of in vitro cell proliferation.
They also observed that NVP-AUY922 resulted in a partial response in the rat model,
as assessed by FDG PET scanning. A smaller study from China, studied the effect of
17-AAG on two cell lines in vitro. They observed that it induced apoptosis in both the
cell lines used, however HSP90 levels were not evaluated (Zhang et al., 2012a).
My study found that endoplasmin was up regulated in cell lines SkChA1 and KKU
M213 but not in HUCC. Considering that KKU M213 is a cell line derived from a Thai
patient this observation is not surprising. SkChA1, a cell line derived from
extrahepatic CCA of a western patient may indicate that endoplasmin is up regulated
in this group too. However, there are no published studies on patient samples to
correlate this finding.
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4.4.8 Lactoylglutathione lyase
Lactoylglutathione lyase, also known as glyoxalase 1 is an essential enzyme in the
pathway that detoxifies methylglyoxal, itself a by-product of glycolysis. Accumulation
of methylglycoxal can induce cell apoptosis although the mechanism has yet to be
elucidated (Thornalley and Rabbani, 2011). Hence, cells with a high glycolytic rate
have a higher detoxification requirement to ensure survival. It is not surprising
therefore that glyoxalase 1 has been found to be overexpressed in a variety of
cancers, such as breast, gastric, colon, prostate and melanoma (Thornalley, 2008).
Expression levels have been linked to survival, with over expression associated with a
poorer prognosis (Cheng et al., 2012). Furthermore, high expression has been linked
to multi drug resistance in cancer chemotherapy (Sakamoto et al., 2000).
The role glyoxalase 1 levels will play in oncology has yet to be established. From the
published studies to date it has yet to find its way in clinical practice, however, it
seems it might have the potential to be used as a prognostic marker and to guide
chemotherapy. Inroads are being made to its use in therapeutics, with the preclinical
development of glyoxalase 1 inhibitors (Thornalley and Rabbani, 2011).
To date, there are no published studies relating to the expression of glyoxalase in
patients with CCA. This study found glyoxalase 1 up regulated in cell lines HUCC and
SKChA1. These results, link CCA cell lines to overexpression of components of the
glycolysis pathway, in a similar fashion to alpha enolase expression, discussed
previously (see section 4.4.1).
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4.4.9 Protein S100A6 (calcyclin)
Protein S100A6, also known as calcyclin, is a 10.5kDa, 90 amino acid protein
belonging to the S100 protein family group. This group consists of about 20 low
molecular weight calcium binding proteins. S100A6 is predominantly a cytoplasmic
protein and binds calcium through its two EF-hand motifs (Schafer and Heizmann,
1996). It is thought to mediate calcium signals in normal and transformed cells.
Cellular processes mediated include mobility, adhesion, proliferation and
differentiation. Its alternative name ‘cal-cyclin’, was coined to reflect its binding
properties to calcium and its involvement in the cell cycle (Lesniak et al., 2009).
Alteration in calcyclin levels have previously been observed in a variety of tumours.
Increased levels have been reported in many alimentary tract cancers such as
colorectal, gastric and pancreatic cancers and levels of expression have been linked
to cancer stage (Komatsu et al., 2000). Reduction in S100A6 was observed in
hepatocellular carcinoma so level determination has been proposed as a method of
differentiating primary with metastatic tumours to the liver (Kim et al., 2002, Melle
et al., 2008).
Kim et al (2002) compared tissue samples from CCA and HCC patients for S100A6
mRNA and protein expression. Comparisons were made between 3 CCA and 6 HCC
biopsies for S100A6 mRNA expression by Northern blotting. Protein expression was
assessed by immunohistochemistry staining of samples from 18 CCA and 20 HCC
patients. The mRNA comparison revealed that all CCA samples expressed calcyclin
transcripts whereas none of the control or HCC ones did. Protein comparison
showed that all CCA samples stained positive to S100A6 to varying degrees. In the
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HCC samples only 2 out of 20 stained positive, both cases being stage IV HCC disease.
The authors concluded that S100A6 levels could be employed as an extra marker to
help distinguish CCA from HCC (Kim et al., 2002).
This study demonstrated increased expression of calcyclin in two cell lines, HUCC and
SkChA1. This correlates with the only published work identified on this protein in
patients with CCA. Calcyclin expression has yet to become a routine laboratory test.
As such, although the results suggest that the observation by Kim et al is supported,
further evidence and proliferation of calcyclin testing would be necessary for the
above authors’ conclusions to be adopted.
4.4.10 Galectin-1
Galectin-1 belongs to a family of 15 proteins, the galectins, which are a subgroup of
lectins. They are defined by the presence of carbohydrate recognition domains
specific to β-galactosides and were first described as a separate entity in 1994
(Barondes et al., 1994). Galectin 1 is a multifunctional protein encountered both in
the intra and extra cellular space and has been linked to various tumour related
processes. It is involved in apoptosis regulation but also in tumour migration,
invasion and angiogenesis.
Galectin 1 leads to the above through its signalling properties. It can bind to CD43
and initiate T-cell mediated apoptosis, in a caspase independent mechanism.
Through binding to laminin, fibronectin, lysosomal-associated membrane proteins
(Lamp 1 and 2) and carcinoembryonic antigen (CEA) it promotes cell adhesion. It also
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binds to neuropilin 1 promoting endothelial proliferation, adhesion and migration
(Barrow et al., 2011).
Within the family of galectins, galectin -1 has been the most extensively investigated,
especially in its relation to cancer. It is over expressed in patient specimens or cell
lines derived from most common tumours. Expression in colorectal, breast, prostate,
lung, pancreatic, HCC and renal cell carcinomas have been shown to be up regulated
through a variety of experimental methods (Demydenko and Berest, 2009).
Furthermore it is over expressed in vascular endothelial cells (Thijssen et al., 2007).
Watanabe et al demonstrated that circulating serum galectin 1 levels measured by
ELISA were significantly higher in patients with colorectal cancer at an early stage
compared to those in controls. Furthermore, galectin 1 levels fell significantly after
surgical resection. They suggested that further evaluation could result in galectin 1
serum testing being a screening test for colorectal cancer (Watanabe et al., 2011).
Shimonshi et al examined expression patterns of galectin in patients with IH CCA,
using immunohistochemistry. Formalin fixed samples from 20 normal bile ducts
were compared to 40 resected samples from patients with CCA and 15 with biliary
dysplasia. All the normal, hyperplastic and dysplastic biliary epithelium samples did
not express galectin 1, whereas 73% of the IH CCA samples were positive. Expression
within this group correlated with tumour stage with higher expression in samples
with higher grade tumours, such as patients with vascular and lymphatic invasion.
Examination of galectin in stromal tissue and surrounding vasculature revealed a
stepwise progression of expression with a weak signal in normal tissue, mild in
dysplastic and strong in CCA samples (Shimonishi et al., 2001).
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More recently, Wu et al validated the above findings by examining galectin 1 level
expression in a cohort of Thai variant IH CCA samples (Wu et al., 2012b).
Comparisons were made between 78 pairs of CCA and adjacent normal liver tissue.
Both FFPE and FF samples were analysed for mRNA and protein level expression.
mRNA was quantified using real time PCR and protein expression by
immunostaining. Both at the genetic and proteomic level galectin-1 was over
expressed. Higher galectin expression was also associated with advancing stage and
poor survival (Wu et al., 2012b).
The extracellular distribution of galectin 1 has led to its proposal as a possible
therapeutic target in cancer. Several agents have been developed, some in academic
units but some by the pharmaceutical industry. Nine agents at various stages of
development have been presented in a recent review (Ito et al., 2012). GM-CT-01
(trade name: Davanat) is an agent prepared from guam gum, a plant extract. It acts
as a galectin 1 inhibitor and is currently the agent furthest in development. It
entered a phase II trial in combination with 5-FU for patients with biliary tree
tumours in 2006, however the study was terminated due to “financing and re-
organisation” issues (NCT00386516).
This study identified over expression of galectin-1 in cell line KKU M213, the cell line
derived from Thailand. This observation correlates with Wu et al providing
supporting evidence that galectin-1 could be of potential value as a diagnostic tool or
a therapeutic target in patients with CCA.
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4.4.11 Thioredoxin
Thioredoxin-1 is a small cytoplasmic protein (12 kDa) present in all organisms that
was first reported in 1964 (Laurent et al., 1964). It is part of the ubiquitous
thioredoxin/thioredoxin reductase redox couple and as part of this system has been
linked to numerous cell processes including the regulation of cell growth and death -
and its dysregulation. Not surprisingly therefore, it has also been linked to
tumourigenesis. Furthermore it has been shown to inhibit both spontaneous and
drug induced apoptosis (Powis and Kirkpatrick, 2007).
The overexpression of either thioredoxin or its reductase, has been reported in a
variety of human tumours including pancreatic, prostate, breast, thyroid, non-small
cell lung carcinoma, malignant melanoma and mesothelioma (Yoon et al., 2006).
Increased levels can be detected by ELISA in plasma and appear to correlate with
poorer outcomes. It has therefore been investigated as a rational druggable target.
PX-12 is the first thioredoxin-1 inhibitor to reach clinical trial evaluation. It is a small
irreversible inhibitor of thioredoxin -1 (Kirkpatrick et al., 1998). Two phase I studies
in patients with solid tumours, demonstrated its safe use although they both
reported cough and halitosis as dose related side effects (Baker et al., 2012,
Ramanathan et al., 2007). A recent phase II trial using PX-12 as monotherapy in
patients with stage IV pancreatic adenocarcinoma was terminated early after
recruiting 16 patients, as all patients showed disease progression within 4 months of
commencing treatment (Ramanathan et al., 2011).
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Thioredoxin expression has also been investigated in CCA. Yoon et al examined
thioredoxin expression by immunohistochemistry in 47 patients with CCA of varying
grades. Although as a group CCA expressed higher levels of thioredoxin when
compared to normal bile ducts, there was no correlation of level of expression with
tumour grade (Yoon et al., 2010).
In my study, thioredoxin was overexpressed in cell line KKU M213 (but not in HUCC-
T1 or SkChA1), an indication that thioredoxin is over expressed at least in some
forms of CCA. This correlates with a study performed by Pak et al where HUCC-T1
cells were exposed to clonorchis sinensis excretory secreted products. The study
intended to replicate the effect of this liver fluke in vitro. Proteomic analysis by mass
spectrometry showed that thioredoxin levels were increased after cell exposure (Pak
et al., 2009). With several other thioredoxin inhibiting agents in the development
pipeline, this protein and pathway could represent a future target for CCA patient
treatment.
4.4.12 Other differentially expressed proteins
Prostaglandin E synthase 3 (PGES-3 also known as p23) is a cytosolic enzyme, part of
the biosynthetic pathway for prostaglandin E (a vasodilator). It also acts as a co-
chaperone for HSP90 (see section 4.4.7) (McLaughlin et al., 2006). In my study it was
found to be overexpressed in cell lines HUCC and SkChA1 which does not correspond
to the same cell lines as for HSP90.
Calmodulin (an acronym for calcium modulated protein) is a calcium-binding
messenger protein. It is an important intracellular mediator of calcium dependant
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signalling. Signals are transduced when calmodulin binds to calcium ions which
modify its interactions with a variety of target proteins. These in turn mediate a
variety of pathways including proliferation, differentiation, and apoptosis (Pawar et
al., 2009). Its differential expression in one of the cell lines (calmodulin was down
regulated only in SkChA1) could represent a fall in overall calcium dependent
signalling, but this does not necessarily relate to the cell cycle.
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5 Conclusions and future directions
Cholangiocarcinoma has been a relatively neglected disease by the scientific
community, more apparent when compared to other cancers. It is particularly
special in that although its incidence is on the increase, on a global scale, patient
numbers remain low, especially in affluent countries. It not so hard to see why the
pharmaceutical industry does not consider CCA as an attractive market, having
invested in just a handful of phase II/III trials treating patients with this disease.
However, momentum in research is gathering, especially in South East Asian
countries and in particular Thailand where the disease incidence is on par with
colorectal and lung cancers. Investment and research in CCA has inevitably followed
the rapid economic development of the country where the GDP per capita has
doubled from approximately US$2,500 to $5,000 in less than a decade.
This study has demonstrated how various chemotherapy combinations can have a
diverse effect on cultured CCA cells. This observation reinforces the emerging
opinion that CCA is less of a single entity and more of a spectrum of closely related
cancers that share an anatomical proximity. It also reinforces the opinion that
intrahepatic CCA differs depending on the risk factors the patient was exposed to,
grossly separating western and South East Asian variant.
This study has also added another piece to the proteomic jigsaw of
cholangiocarcinoma. The results indicate an enigmatic puzzle, with a small subset of
the total proteome (10-20%) being altered in the CCA cell lines compared with the
cholangiocyte cell line. This subset of differentially-expressed proteins are broadly
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speaking the same in all three CCA cell lines, but with each protein in the subset
cohort usually being up-regulated in some cell lines but down-regulated in others.
However, when viewed in terms of their biological function, it is noteworthy that the
differential proteins are principally cellular defence proteins or are calcium-binding
and are therefore potentially involved in cell signalling. In all instances, up-regulation
was more common than down-regulation amongst the differentially-expressed
proteins, suggesting that targeting gene expression is a valid means of controlling
CCA. There were no obvious differences between the intra-and extra-hepatic cell
lines, with “only” one identified protein being uniquely up-regulated (ATP synthase)
and one uniquely downregulated (gamma-synuclein) in the HUCC extra-hepatic cell
line compared to the cholangiocyte cell line. The cell line that was most “unique”
was SkChA1, with 56 spots upregulated and 98 spots downregulated compared to
the cholangiocyte cell line. However, most of these were of low abundance and
unfortunately could not be identified. SkChA1 is derived from a Western CCA yet it
differs more extensively from the cholangiocyte cell line than the Thai intrahepatic
equivalent cell line (M213, where 29 spots were uniquely upregulated and 43
uniquely downregulated compared with the cholangiocyte cell line). This suggests
that if the O. viverrini parasite does induce CCA as indicated by Sripa et al., (2012)
and others, the resultant disease is more differentiated than Western CCA, and
therefore possibly more difficult to treat.
Most of the highlighted proteins have been identified in other cancers as well. This
observation could be interpreted as a disadvantage as it arguably reduces the
chances of finding a diagnostic tool differentiating unique to CCA. However, in the
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context of this being a rare disease, it could also be seen as an advantage: any
molecular targeted treatments in development for other cancers could potentially
translate to CCA.
This study also highlights the role that novel agents might have in the treatment of
CCA. The cytotoxic studies demonstrated that a benzodiazepine receptor antagonist
enhanced cytotoxic action in an in vitro setting. Agents such as this one are gradually
gaining favour at a clinical level in other cancers so the observations in this study
show that they may also have a role in the treatment of CCA.
As with other solid cancers, treatment is ultimately shifting towards the tailoring of
treatment (including chemotherapy) to the individual patient. The use of a panel of
expressed proteins, often referred to as molecular profiling or protein fingerprinting,
is thought to be the future of such treatment. Preclinical studies such as this one
help provide theoretical guidance for directions to be followed in the clinical setting.
Such evidence is all the more important in the investigation of the more rare
diseases where patient access is a problem.
It is clear that the findings of this study need to be further validated in real patient
samples. As outlined in the introduction to Chapter 4, to date, very few studies have
investigated the CCA proteome at patient histology level, and those that have used a
very limited number of patients.
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Abbreviations
Listed in alphabetical order
2DE 2 Dimensional Electrophoresis
5-FU 5-Fluorouracil
96WP 96 Well Plate
AJCC American Joint Cancer Committee
ANOVA Analysis of variance
ASBT Apical Sodium Dependent Bile Acid Transporter
Bcl B-cell lymphoma
Bp Base pairs
Ca 19-9 Carbohydrate antigen 19-9
Cat no Catalogue Number
CCA Cholangiocarcinoma
cDNA Complementary DNA
CEA Carcinoembryonic antigen
CGH Comparative genomic hybridisation
CHAPS 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate
CI Confidence Interval
CK 19 Cytokeratin 19
CK7 Cytokeratin 7
CN Copy Number
COX Cyclooxygenase
DAPI 4',6-diamidino-2-phenylindole
ddH2O Double distilled water
DIGE Differential In Gel Electrophoresis
DMEM Dulbeccos Modified Eagle Medium
DMF N,N-Dimethylformamide
DMSO Dimethylsulphoxide
DNA Deoxyribonucleic acid
DTT DL-Dithiothreitol
EDTA Ethylenediaminetetraacetic Acid
EH Extra Hepatic
ELISA Enzyme-Linked Immunosorbent Assay
EMA Epithelial Membrane Antigen
EtOH Ethanol
FCS Foetal Calf Serum
FISH Fluorescent in situ hybridisation
GB Gallbladder
GDP Gross Domestic Product
H&E Haematoxylin and Eosin
HCC Hepatocellular carcinoma
HCSG Human Cancer Studies Group
HPB Hepatopancreatobiliary
IC50 Half maximal inhibitory concentration
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IH Intra Hepatic
IL Interleukin
iNOS inducible Nitric Oxide Synthase
IPG Immobilised Ph Gradient
LCSGJ Liver Cancer Study Group of Japan
MALDI Matrix-assisted laser desorption/ionization
Mb Megabases
Mcl Myeloid cell leukaemia
MS Mass Spectrometry
m/z Mass / charge
MRA Magnetic Resonance Angiography
MRCP Magnetic Resonance Cholangiopancreatography
MRI Magnetic Resonance Imaging
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
NCCJ National Cancer Center of Japan
NCT National Clinical Trial
NEAA Non Essential Amino Acids
NNDMF Diemethyl Formamide
NTCP Na+ dependent Taurocholate Co-transporting Polypeptide
OD Optical Density
OS Overall Survival
PAGE Polyacrylamide gel electrophoresis
PBS Phosphate Buffered Saline
PDGF Platelet Derived Growth Factor
PFS Progression Free Survival
PMID PubMed Identification
PMT Photomultiplier Tube
PMF Peptide mass fingerprint
RCT Randomised Controlled Trial
RNA ribonucleic acid
rpm Rotations (revolutions) per minute
RPMI Roswell Park Memorial Institute
SDS sodium dodecyl sulfate
SRB Sulforhodamine B
TACE Trans- arterial chemoembolisation
TBP Tributylphosphine
TCA Trichloroacetic Acid
TEMED Tetramethylethylenediamine
TGF Tumour Growth Factor (aka Transforming Growth Factor)
TNF Tumour Necrosis Factor
TCTP Translationally controlled tumour protein
TRAIL Tumour necrosis factor related apoptosis inducing ligand
UICC Union for International Cancer Control
UK United Kingdom
US United States
V Volts
Vh Volt hours
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Materials, solutions and reagents
Reagent Company Catalogue Number
2-D Clean-Up Kit GE Healthcare 80-6484-51
4-hydroxy-α-cyano-
cinnamic acid
Sigma-Aldrich 50149-1G-F
5-Flurouracil Sigma-Aldrich F6627
Acetic Acid VWR 20104.298
Acrylamide Sigma-Aldrich 01709
Adenine Sigma-Aldrich A2786
Albumin Sigma-Aldrich A9418
Ammonium persulphate Sigma-Aldrich A9164
Ammonium bicarbonate Sigma-Aldrich 09830
Anti mouse antibody Jackson ImmunoResearch 715-166-150
Acetonitrile (aqueous) Sigma-Aldrich 34998
Bio-Safe™ Coomassie Stain Bio-Rad Laboratories 161-0786EDU
Bromophenol blue Sigma-Aldrich B5525
Chamber slide LabTek 177402
CHAPS Sigma-Aldrich C9426
Cisplatin Enzo Life Sciences ALX-400-040-M050
CK7 DAKO IR618/IS618
CK19 DAKO IR615/IS615
Cy3 DIGE Fluor GE Healthcare 25-8010-83
Cy5 DIGE Fluor GE Healthcare 25-8008-62
DAPI Sigma-Aldrich D9542
DMEM Gibco-Invitrogen 21969
DMEM with high glucose Gibco-Invitrogen 11095098
DMSO Sigma-Aldrich D4540
DPBS Gibco-Invitrogen 14190250
DTT Sigma-Aldrich D9779
EMA DAKO IR629/IS629
Eosin Sigma-Aldrich HT110116
Epidermal Growth Factor Millipore 01-102
Epinephrine Sigma-Aldrich E4250
Etoposide Sigma-Aldrich E1383
Foetal calf serum Sigma-Aldrich N4637
Gemcitabine (Gemzar) Lilly pharmaceuticals 7502
Gentamicin Sigma-Aldrich G1272
Glycerol Sigma-Aldrich G5516
Hematoxylin Sigma-Aldrich H3136
Hydrocortisone Sigma-Aldrich H0888
Insulin Sigma-Aldrich I2643
Iodoacetamide Sigma-Aldrich I1149
L-Glutamine Gibco-Invitrogen 25030081
Lysine Sigma-Aldrich L5501
Protease Inhibitor Mix GE Healthcare 80-6501-23
Materials, solutions and reagents
191
Methanol VWR BDH 101586B AnalR
NaOH Sigma-Aldrich 71690
NEAA (x100) Gibco-Invitrogen 11140
NNDMF Sigma-Aldrich D4551
P11195 Sigma-Aldrich C0424
Paraformaldehyde VWR 28794.295
PBS Sigma-Aldrich P4417/P5244
Penicillin/Streptomycin Gibco-Invitrogen 15140155
Penicillin/Streptomycin Sigma-Aldrich 15140-122
PK11195 Sigma-Aldrich C0424 (10mg)
Power Block Biogenex HK085-5K
RNeasy Mini Kit Qiagen 74104
SDS Sigma-Aldrich L4390
SRB Sigma-Aldrich S9012 (5g)
TCA Sigma-Aldrich T6399
TEMED Sigma-Aldrich T9281
TGS BioRad 161-0772
Thiurea Sigma-Aldrich T8656
Transferrin Sigma-Aldrich T2036
Trizma HCL Sigma-Aldrich T3253
Trifluoroacetic acid Sigma-Aldrich T6508
Tris Base Sigma-Aldrich T1503
Trizma base Sigma-Aldrich T1503
Trypan Blue Sigma-Aldrich T8154
Trypsin – EDTA solution Sigma-Aldrich T4174 (10x)
Trypsin (porcine) Promega V511A
Trypsin (proteomics) Promega 608-274-4330
Urea Sigma-Aldrich U6504
β- actin Applied Biosystems 4310881E
DMEM/F-12 Gibco-Invitrogen 11330057
IPG buffer (pH 3-11) GE Healthcare 17-6004-40
Ethanol (100%) VWR 20820.327
3,3 Triiodo-l-thyronine Sigma-Aldrich T6397
Pierce 660 Thermo Scientific 22660
RPMI 1640 Sigma-Aldrich R5886
Kits and Assays
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Kits and Assays
cDNA Reverse
Transcription Kit
Invitrogen 4368814
High Capacity cDNA
Reverse Transcription Kit
Applied Biosystems 4368814
TaqMan Gene Expression
Assay
Applied Biosystems Hs00236329_m1
Related publications and presentations
193
Related publications and presentations
Pericleous S;Mathieson W; Middleton N; McKay S; Biswas A; Thomas G; Spalding
DR; Hutchins RR. PK11195, a peripheral benzodiazepine receptor ligand, potentiates
cytotoxic action on cholangiocarcinoma cell lines. European-African Hepato
Pancreatic Biliary Association, 12 Apr 2011 - 16 Apr 2011. (Suppl. 2):1-145.
Pericleous S, SC McKay, W Mathieson, K Unger, DR Spalding, RR Hutchins, G Thomas,
G Stamp Array Comparative Hybridisation to Cholangiocarcinoma Cell Lines HuCC-T1
and SkChA-1. Presented at the Pathological Society Scientific Meeting London , 8–9
January 2010 Abstract published in: The Journal of Pathology, Volume 220, Issue S1
(p S1-S27)  DOI: 10.1002/path.2705
Pericleous S et al. Chemotherapy for cholangiocarcinoma; the effect of dual versus
monotherapy on multiple cell lines. The Association for Cancer Surgery Scientific
Conference (British Association of Surgical Oncology), (November 2010).
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comparative genomic hybridization identifies novel potential therapeutic targets for
cholangiocarcinoma. - Abstract number: 7614627 Presented at the 9th World
Congress of the International Hepato-Pancreato-Biliary Association April 18-22,
2010, Buenos Aires. Abstract published in: HPB Journal 12 (Suppl. 1), 1–468. DOI:
10.1111/j.1477-2574.2010.00165.x (Presentation FP-25)
McKay S, Unger K, Sriraksa R, Zeller C, Pericleous S et al. Differing copy number
alteration profiles identified by array CGH in Thai Intrahepatic Cholangiocarcinoma
Related publications and presentations
194
related to prognosis . (Abstract 1291)  The Liver Meeting 2010 - The American
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